Dopaminergic neurons containing mutations and methods of use thereof

iPSC-derived dopaminergic neuron cell lines with GBA, LRRK2, or SNCA mutations offer a detailed in vitro model for Parkinson's disease, enhancing therapeutic screening and early diagnosis through increased dopamine release and stress susceptibility.

JP2024541964AInactive Publication Date: 2024-11-13CELLULAR DYNAMICS INTERNATIONAL +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024525222
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-29
Filing Date
2022-10-28
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is an unmet need for dopaminergic neurons with disease-associated mutations for disease modeling and therapeutic screening, as existing models do not adequately replicate the physiological and genetic characteristics of neurodegenerative conditions like Parkinson's disease.

Method used

The development of induced pluripotent stem cell (iPSC)-derived dopaminergic neuron cell lines containing mutations in glucosylceramidase (GBA), leucine-rich repeat kinase 2 (LRRK2), or alpha-synuclein (SNCA) to create models that mimic the genetic and physiological features of Parkinson's disease, along with associated kits and cultures for therapeutic screening.

Benefits of technology

These models provide an embryologically and physiologically relevant in vitro system for studying neurodegenerative diseases, enabling effective screening of therapeutic agents and understanding disease mechanisms, including increased dopamine release and susceptibility to oxidative stress, which can aid in early diagnosis and treatment development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541964000003
    Figure 2024541964000003
  • Figure 2024541964000004
    Figure 2024541964000004
  • Figure 2024541964000005
    Figure 2024541964000005
Patent Text Reader

Abstract

The present disclosure provides iPSC-derived dopaminergic neurons that contain disease-related mutations.Further provided herein is a method for using iPSC-derived dopaminergic neurons to study neuroinflammation, such as identifying new targets, biomarkers, and therapeutics for the diagnosis, prognosis, and treatment of neurodegenerative diseases.Further provided herein is an assay for studying neuroinflammation using this cell culture model.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Claiming priority This application claims the benefit of U.S. Provisional Patent Application No. 63 / 273,480, filed October 29, 2021, the entire contents of which are incorporated herein by reference.

[0002] This application contains a sequence listing XML that has been submitted electronically and is incorporated herein by reference in its entirety. The XML sequence listing, created on October 27, 2022, has the file name CDINP0111WO.xml and is 1,933 bytes in size. [Background technology]

[0003] 1. Field The present invention relates generally to the fields of molecular biology and medicine. More specifically, the present invention relates to compositions and methods of use of neurons differentiated from induced pluripotent stem cells (iPSCs).

[0004] 2. Description of Related Technology Human iPSC-derived dopaminergic neurons provide a developmentally and physiologically relevant in vitro model of human midbrain dopaminergic neurons that innervate various regions of the central nervous system (CNS), including the forebrain and striatum. Loss of dopaminergic neurons leads to reduced dopamine levels in the CNS, resulting in neurodegenerative conditions, including Parkinson's disease (PD). Dopaminergic neurons decrease with age and are selectively vulnerable to oxidative stress caused by dopamine oxidation, which increases with age. There is an unmet need for dopaminergic neurons with disease-associated mutations in disease modeling. Summary of the Invention [Means for solving the problem]

[0005] In some embodiments, the present disclosure provides isolated induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neuronal cell lines comprising a glucosylceramidase (GBA) mutation, a leucine-rich repeat kinase 2 (LRRK2) mutation, or an alpha-synuclein (SNCA) mutation.

[0006] In some embodiments, the cell line has a GBA N370S mutation or a LRRK2 G2019S mutation. In certain embodiments, the cell line has a GBA N370S mutation, a GBA L444P mutation, or a GBA RecNil mutation. In certain embodiments, the cell line has a GBA N370S mutation. In certain embodiments, the cell line has a LRRK2 G2019S mutation, a LRRK2 R1441G mutation, a LRRK2 R1441C mutation, or a LRRK2 I2020T mutation. In certain embodiments, the cell line has a LRRK2 G2019S mutation. In certain embodiments, the cell line has a SNCA A53T mutation, a SNCA E46K mutation, a SNCA duplication, or a SNCA triplet. In some embodiments, the cell line has a SNCA A53T mutation.

[0007] In some embodiments, the iPSC-derived dopaminergic neurons iPSCs are genetically engineered to contain a GBA mutation, a LRRK2 mutation, or a SNCA mutation.

[0008] In some embodiments, the iPSC of the iPSC-derived DA neuron cell line is the iPSC that is episomally reprogrammed from a donor with neurodegenerative disease.In certain embodiments, the iPSC of the iPSC-derived DA neuron is the iPSC that is episomally reprogrammed from a donor with Parkinson's disease.

[0009] In some embodiments, the cell line is a human cell line. In certain embodiments, the iPSC-derived dopaminergic neurons are midbrain dopaminergic neurons. In some embodiments, the iPSC-derived dopaminergic neurons are terminal dopaminergic neurons that express FOXA2 and tyrosine hydroxylase (TH). In certain embodiments, the iPSC-derived dopaminergic neurons have at least 50% increased TH, DDC, MAOA, and / or COMT transcription levels compared to DA neurons differentiated from iPSCs reprogrammed from healthy donors that do not have disease-associated mutations. In certain embodiments, the iPSC-derived dopaminergic neurons have at least 30% increased release of dopamine in response to KCl stimulation compared to DA neurons differentiated from iPSCs reprogrammed from healthy donors that do not have disease-associated mutations. In some embodiments, iPSC-derived dopaminergic neurons have increased cell death, mitochondrial stress, and alpha-synuclein protein aggregation compared to DA neurons differentiated from iPSCs reprogrammed from healthy donors without disease-associated mutations. In certain embodiments, iPSC-derived dopaminergic neurons containing SNCA mutations have reduced lysosomal GCase activity compared to DA neurons differentiated from iPSCs reprogrammed from healthy donors without disease-associated mutations. In certain embodiments, iPSC-derived dopaminergic neurons containing SNCA mutations have reduced lysosomal GCase activity compared to DA neurons differentiated from iPSCs reprogrammed from healthy donors without disease-associated mutations. In some embodiments, iPSC-derived dopaminergic neurons lack intracellular calcium signaling as measured by RNA sequencing and calcium imaging. In certain embodiments, the cell line is isogenic.

[0010] Further embodiments provide kits comprising the cell lines of the embodiments (e.g., isolated induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neuronal cell lines comprising a glucosylceramidase (GBA) mutation, a leucine-rich repeat kinase 2 (LRRK2) mutation, or an alpha-synuclein (SNCA) mutation) in a suitable container.

[0011] In some embodiments, the kit comprises an iPSC-derived DA neuron cell line comprising a GBA N370S mutation in a first container, and an iPSC-derived DA neuron cell line comprising an LRRK2 G2019S mutation in a second container. In certain embodiments, the kit further comprises an iPSC-derived DA neuron cell line that does not have a disease-associated mutation. In certain embodiments, the iPSCs of the iPSC-derived DA neuron cell line are episomally reprogrammed iPSCs from a healthy donor, such as a healthy donor that does not have a neurodegenerative disease. In some embodiments, the kit further comprises an iPSC-derived DA neuron cell line engineered to express a disease-associated mutation in a third container. In certain embodiments, the disease-associated mutation is a mutation in alpha-synuclein (SNCA). In some embodiments, the mutation in SNCA is a missense point mutation, such as A53T.

[0012] In some embodiments, the kit further comprises astrocytes, pericytes, brain microvascular endothelial cells, microglia, and / or neurons, each in a suitable container. In certain embodiments, the kit further comprises reagents for detecting dopamine levels, GBA activity, neuronal maestro multi-electrode array (MEA) activity, and α-synuclein-mediated protein aggregation, each in a suitable container. In further embodiments, the kit further comprises reagents for measuring TH, DDC, MAOA, and / or COMT transcript levels. In certain embodiments, the reagents are further defined as enzyme-linked immunosorbent assay (ELISA) reagents. In some embodiments, the kit further comprises an ELISA plate. In some embodiments, the kit further comprises reagents for detecting glucocerebrosidase (GCase) activity and / or for performing calcium imaging.

[0013] Further provided herein is the use of the kit of the present embodiment (e.g., a kit comprising the cell line of the present embodiment (e.g., an isolated induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neuronal cell line comprising a glucosylceramidase (GBA) mutation, a leucine-rich repeat kinase 2 (LRRK2) mutation, or an alpha-synuclein (SNCA) mutation) contained in a suitable container) for detecting a neurodegenerative disease. In some embodiments, the neurodegenerative disease is Parkinson's disease.

[0014] Another embodiment provides use of a kit of the present embodiment (e.g., a kit including a cell line of the present embodiment (e.g., an isolated induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neuronal cell line comprising a glucosylceramidase (GBA) mutation, a leucine-rich repeat kinase 2 (LRRK2) mutation, or an alpha-synuclein (SNCA) mutation) contained in a suitable container) for screening of therapeutic agents for the treatment of neurodegenerative diseases.

[0015] In yet another embodiment, there is provided use of a kit of the present embodiment (e.g., a kit including a cell line of the present embodiment (e.g., an isolated induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neuronal cell line comprising a glucosylceramidase (GBA) mutation, a leucine-rich repeat kinase 2 (LRRK2) mutation, or an alpha-synuclein (SNCA) mutation) contained in a suitable container) as a model for Parkinson's disease.

[0016] Another embodiment provides a culture comprising DA neurons derived from iPSCs that contain a GBA N370S mutation, a LRRK2 G2019S mutation, or a SNCA A53T mutation.

[0017] In some embodiments, the culture comprises DA neurons derived from iPSCs that comprise a GBA N370S mutation. In certain embodiments, the culture comprises DA neurons derived from iPSCs that comprise a LRRK2 G2019S mutation. In some embodiments, the culture comprises DA neurons derived from iPSCs that comprise a SNCA A53T mutation.

[0018] In certain embodiments, the cell culture is a two-dimensional (2D) culture. In some embodiments, the medium comprises DAPT. In certain embodiments, the cells are cultured on a surface coated with an extracellular matrix protein. For example, the extracellular matrix is ​​basement membrane extract (BME) purified from mouse Engelbreth-Holm-Swarm tumors. In some embodiments, the extracellular matrix protein is MATRIGEL®, GELTREX™, collagen, or laminin. In some embodiments, the cell culture is a three-dimensional (3D) culture.

[0019] In some embodiments, the cell culture further comprises astrocytes, pericytes, brain microvascular endothelial cells, microglia, and / or other types of neurons.

[0020] In some embodiments, the iPSCs are human. In some embodiments, the culture is xeno-free, feeder-free, and / or conditioned medium-free. In certain embodiments, the medium is a defined medium.

[0021] Further provided herein is the use of the cultures of the present embodiments (e.g., cultures comprising DA neurons derived from iPSCs comprising a GBA N370S mutation, a LRRK2 G2019S mutation, or a SNCA A53T mutation) as models for neurodegenerative disease. In some embodiments, the models include cultures comprising DA neurons derived from iPSCs comprising a GBA N370S mutation, DA neurons derived from iPSCs comprising a LRRK2 G2019S mutation, DA neurons derived from iPSCs from healthy donors, or DA neurons derived from iPSCs engineered to express a SNCA A53T mutation.

[0022] Another embodiment provides a method of screening for a therapeutic compound for treating a neurodegenerative disease, comprising contacting a test compound with an iPSC-derived DA neuron of the embodiment or a culture of the embodiment (e.g., a culture comprising an iPSC-derived DA neuron comprising a GBA N370S mutation, a LRRK2 G2019S mutation, or an SNCA A53T mutation) and measuring the functional activity, physiology, or viability of the cell.

[0023] In some embodiments, an increase in functional activity indicates that the test compound can treat the neurodegenerative disease. In certain embodiments, the method includes measuring the level of dopamine. In some embodiments, the method further includes contacting the cell line with KCl. In some embodiments, measuring functional activity includes measuring glucocerebrosidase (GCase) activity. In certain embodiments, an increase of at least 10% in GCase activity identifies the candidate compound. In some embodiments, the method further includes performing a calcium imaging assay to measure calcium oscillations. In some embodiments, measuring calcium oscillations includes measuring one or more of the following measurements: peak number, peak rate, and area under the curve. In certain embodiments, the measured calcium oscillations can be associated with AHN neurons or mutant neurons. In some embodiments, measuring calcium oscillations can be used for compound screening.

[0024] In certain embodiments, measuring functional activity comprises measuring GBA activity, MEA activity, alpha-synuclein mediated protein aggregation, and / or mitochondrial ROS levels. In some embodiments, the level of dopamine is measured by an ELISA assay, such as competitive dopamine ELISA. In some embodiments, measuring the level of dopamine comprises measuring dopamine mRNA and / or protein levels. In certain embodiments, an increase of at least 30% or more than 30 ng / mL of dopamine is indicative of a candidate compound.

[0025] In some embodiments, the method further comprises measuring TH, DDC, MAOA, and COMT transcript levels. In certain embodiments, alpha-synuclein protein aggregation is measured by thioflavin staining and alpha-synuclein expression.

[0026] In certain embodiments, the neurodegenerative disease is Parkinson's disease.

[0027] In some embodiments, an at least 1.5-fold increase in RNA expression of TH, DDC, MAOA, and / or COMT identifies a candidate compound. In certain embodiments, an increase in MEA activity identifies a candidate compound. In some embodiments, an at least 30% increase in α-synuclein expression and aggregation and / or mitochondrial ROS identifies a candidate compound. In certain embodiments, an at least 50% decrease in GBA activity identifies a candidate compound.

[0028] Another embodiment provides a method for screening for a neurodegenerative disease, the method comprising contacting an iPSC-derived DA neuron containing a GBA N370S mutation or a LRRK2 G2019S mutation with a sample.

[0029] In some embodiments, the method further comprises contacting an iPSC-derived DA neuron comprising an SNCA A53T mutation with the sample. In some embodiments, the iPSC-derived DA neuron comprising a GBA N370S mutation and / or the iPSC-derived DA neuron comprising an LRRK2 G2019S mutation is a cell according to the present embodiment. In some embodiments, the sample is a patient sample. In certain embodiments, the sample is a blood sample. In some embodiments, the method further comprises detecting a level of dopamine. In certain embodiments, an increase in the level of dopamine indicates the presence of a neurodegenerative disease. In some embodiments, the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, or multiple sclerosis.

[0030] Other objects, features and advantages of the present invention will become apparent from the following detailed description, but it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

[0031] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. [Brief description of the drawings]

[0032] [Fig. 1A-1F] Generation and characterization of iPSCs for PD modeling. (Figure 1A) Episomal reprogrammed iPSC 01279 was engineered to generate heterozygous (HZ) SNCA A53T mutant lines. The engineering is illustrated diagrammatically, with the amino acid 53 alanine to threonine change highlighted in yellow. (Figure 1B) IPSCs derived from a PD patient with a GBA N370S mutation. The amino acid change of asparagine 370 to serine highlighted in yellow. (Figure 1C) IPSCs derived from a PD patient with a mutant LRRK2 G2019S mutation diagrammatically, with the amino acid change of glycine 2019 to serine highlighted in yellow. (Figure 1D-1F) Cytogenetic analysis of G-banded metaphase cells from each iPS cell line detailing normal karyotype, SNCA A53T, GBA(N370S), and LRRK2(G2019S).

[0033] [Figure 2A-2C] Generation and characterization of dopaminergic neurons from apparently healthy normal (AHN) iPSCs, engineered isogenic iPSCs, and PD patients for disease modeling. (Figure 2A) Schematic diagram of the chronological differentiation process of iPSCs into dopaminergic neurons and the cytokines utilized throughout the process. (Figure 2B) Representative flow cytometry dot plot of dopaminergic progenitor cells at day 17 expressing midbrain transcription factors FOXA2 and LMX1. (Figure 2C) Representative flow cytometry dot plot of dopaminergic neurons at the end of the process expressing FOXA2 and tyrosine hydroxylase (TH) enzyme, an enzyme required for dopamine synthesis from tyrosine.

[0034] [Figure 3A-3C] (FIGS. 3A-3B) Immunofluorescence staining of terminal DA neurons. (FIG. 3C) Quantitative flow cytometry analysis of FOXA2 and TH proteins in dopaminergic neurons.

[0035] [Figure 4A-4C] GBA and LRRK2 PD patient iPSC-derived DA neurons show abnormal mRNA and protein expression of enzymes involved in dopamine synthesis and degradation. (FIG. 4A) Quantification of TH, DDC, MAOA, and COMT transcript levels in ANH, engineered, and PD patient-derived DA neurons. (FIG. 4B) Quantification of TH and DDC protein levels in ANH, engineered, and PD patient-derived DA neurons. (FIG. 4C) Quantification of TH and DDC protein based on the area under the curve for each protein and normalized to MAPT expression. (*P value<0.05, **P value<0.01, ***P value<0.001).

[0036] [Figure 5A-5B] DA neurons derived from GBA and LRRK2 PD patient iPSCs release more dopamine when stimulated with KCl. (Figure 5A) Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated for 21 days according to the manufacturer's instructions, and the levels of dopamine released by the cells were quantified using a competitive dopamine ELISA (Eagle Biosciences Cat. No. DOP31-K01). Standard curves graphed in Graphpad PRISM are shown. (Figure 5B) Dopamine release of DA neurons was compared to dopamine released by AHN DA neurons at day 21 of culture in HBSS buffer stimulated with KCL (*P value < 0.05, **P value < 0.01, ***P value < 0.001).

[0037] [Figures 6A-6E]DA neurons derived from SNCA-manipulated iPSCs and PD patient iPSCs reveal higher cell death and mitochondrial stress. (Figure 6A) Representative staining of terminal DA neurons with 1 μM YOYO-3 iodide (dead cells) and calcein AM (live cells) at different time points. (Figure 6B) Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated. The percentage of live / dead cells was calculated based on positive objects in the green and red channels. The data show live cells per well (0.143 cm2) of a 96-well plate. (Figure 6C) Representative images of DA neurons stained with MitoSOX dye (left image), overlaid with phase images (middle image), and co-stained with calcein AM for live cells (right image). (FIGS. 6D-6E) Quantification of MitoSOX signal intensity (mean ± SD) and percentage of MitoSOX positive cells in diseased neurons compared to AHN neurons. (*P value < 0.05, **P value < 0.01, ***P value < 0.001)

[0038] [Figure 7A-7C] DA neurons derived from SNCA-engineered iPSCs and PD patient iPSCs have significantly more aSyn protein aggregates. (Fig. 7A) Thioflavin (Th-T) staining was performed to reveal aggregated aSyn on live DA neuron cultures at 22 DIV after addition of oligomeric aSyn (4 μM / ml) for 24 h. (Fig. 7B) Total aSyn+ cells were counted and plotted against Th-T signal intensity in individual neurons of different expression bins. (Fig. 7C) Th-T images were quantified for DA neuron cultures at 21 DIV treated with active oligomeric aSyn for 24 h, 48 h, or 72 h (n=4, one-way ANOVA with Dunnett's multiple comparison test).

[0039] [Figure 8A-8C]DA neurons derived from SNCA engineered iPSCs and PD patient iPSCs have greater aSyn aggregation. (Figure 8A) Quantification of α-synuclein protein aggregation using the Mesoscale Diagnostics (MSD) U-PLEX Human α-Synuclein Kit (MSD-K15). Analyte concentrations were determined from the ECL signal by backfitting to a standard curve. (Figure 8B-C) Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were assayed for 21 or 42 days in culture.

[0040] [Figure 9A-9F] DA neurons derived from SNCA-manipulated iPSCs and PD patient iPSCs have low GCase activity. Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated for 14 days, and samples were collected and submitted for RNASeq and Western blot analysis. FPKM values ​​of GBA transcripts were quantified (Figure 9A). The amount of GBA protein in the lysates was quantified based on the area under the curve for each protein and normalized to MAPT expression (Figure 9B). Different concentrations of 4-methylumbelliferyl-β-D-glucopyranoside (4-MU) as substrate (Figure 9C) and the GCase-specific inhibitor conduritol B epoxide (CBE) (Figure 9D) were tested. 10 mM 4-MU and 2 mM CBE were found to be the optimal concentrations and were used for the following GCase activity assay. Different concentrations of protein lysate were also tested for GCase activity from AHN DA neurons (Figure 9E). 5ug of protein lysate was used to compare GCase activity between different DA neurons (Figure 9F). (n=4, p<0.001 one-way ANOVA with Dunnett's test for mean comparison). (*P value<0.05, **P value<0.01, ***P value<0.001).

[0041] [Figure 10A-10B]DA neurons derived from SNCA engineered iPSCs and PD patient iPSCs reveal differences in the evolution of neural network activity. Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated in complete BrainPhys medium in 48-well Classic multielectrode array (MEA) plates (8 wells per lot at a cell density of 120K cells per well). Neuronal activity was quantified using an Axion MaestroMEA. Quantification of burst rate, network burst frequency, and synchronization index over time (Figure 10B) revealed lower activity and network strength in GBA, LRRK2, and SNCA neurons compared to AHN cells in raster plots at day 35 (Figure 10A).

[0042] [Figures 11A-11C] RNAseq data analysis 14 days after thawing. Mutant DA neuron transcripts were plotted against AHN DA neurons, showing high correlation in gene expression levels, with significantly different transcripts highlighted in color (Figure 11A). Differential gene expression analysis was performed for mutant samples compared to AHN samples, and the number of significantly changed transcripts was summarized in a Venn diagram (Figure 11B). Gene set enrichment and pathway analysis of differentially regulated transcripts in mutant DA neurons compared to AHN DA neurons in the DAVID database. Pathways highlighted in color were commonly regulated pathways in all mutant DA neurons (Figure 11C).

[0043] [Figures 12A-12C]Compound screening with a panel of iPSC-derived DA neurons. (Figure 12A) Effect of 12 compounds at three concentrations on Gcase activity in GBA and LRRK2 DA neurons with AHN as a control. (Figure 12B) In the combination screen, four molecules from the first screen showing improved GCase activity were picked up and combined in different ways to test in GBA cells. Single compounds were tested for both acute (3 days) and chronic (2 weeks) exposure. The combination screen showed that chronic treatment with 10 uM ambroxol had the highest GCase activity in GBA cells. (Figure 12C) This was further tested in LRRK2, SNCA, and GBA compared to AHN. 21 days after thawing, treatment with 10 uM ambroxol for 2 weeks significantly increased Gcase activity in all mutant neurons. (Dotted lines indicate Gcase levels of DMSO vehicle control, ***P value < 0.001)

[0044] [Figure 13A-13D] Calcium imaging of iPSC-derived DA neurons. Calcium oscillation traces in DA neurons 14 days after plating were captured for 20 minutes using the FDSS / μCELL instrument. (Figure 13A) Baseline measurements of Ca oscillations in AHN and all three mutants after one week of treatment with 10 uM ambroxol. Compared to untreated AHN DA neurons, treatment with ambroxol caused hyperexcitability in AHN, LRRK2, and SNCA DA neurons, but rescued the peak number and peak rate in GBA mutant DA neurons. Calcium transient characteristics, including (Figure 13B) peak number, (Figure 13C) peak rate per minute, and (Figure 13D) peak amplitude (mean), were quantified for all wells (replicates) of each cell line using Waveform software. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0045] In certain embodiments, the present disclosure provides human iPSC-derived dopaminergic neurons carrying disease-associated mutations. Further provided herein is the use of these cells as a developmentally and physiologically relevant in vitro model of human midbrain dopaminergic neurons that innervate various regions of the CNS, including the forebrain and striatum.

[0046] Loss of dopaminergic neurons causes a decline in dopamine levels in the CNS, resulting in neurodegenerative conditions including Parkinson's disease (PD). Dopaminergic neurons are selectively vulnerable to oxidative stress produced by dopamine oxidation, which declines with age and increases with age. This study outlines the generation and characterization of iPSC-derived dopaminergic neurons from two PD patients who inherited either GBA (N370S) or LRRK2 (G2019S) mutations (GBA and LRRK2 lines are part of the Parkinson's Progression Markers Initiative (PPMI) iPSC bank) and genetically engineered SNCA A53T iPSCs. End-stage dopaminergic neurons derived from healthy and PD donors were assessed for GBA activity, neuronal MEA activity, and α-synuclein-mediated protein aggregation. These results recapitulated many hallmarks of PD in a dish. Specifically, this study demonstrated that GBA- and LRRK2-derived DAs produced and released more dopamine compared to AHN DAs. GBA and LRRK2 DAs also showed high α-synuclein aggregation comparable to SNCA DAs. Furthermore, all mutant DAs (GBA, LRRK2, and SNCA) showed lower GBA activity, and their neuronal network activity developed faster compared to AHN DAs, but then decreased over time.

[0047] Thus, this panel of human iPSC-derived dopaminergic neurons harboring disease-specific mutations can be used in a variety of in vitro applications to reveal mechanistic insights into dopaminergic neuron degeneration and the identification of novel therapeutic targets.

[0048] Thus, in certain embodiments, the present disclosure provides in vitro culture models for the study of neuroinflammation, including identifying novel targets, biomarkers, and therapeutics for the diagnosis, prognosis, and treatment of neurodegenerative diseases such as Parkinson's disease. In certain aspects, the cells and models can be used to detect the early onset of Parkinson's disease.

[0049] Further provided herein are assays for studying neuroinflammation using this cell culture model. The results of this model can be GBA activity, neuronal MEA activity, mitochondrial oxidative stress and membrane potential, lysozyme and autophagy activity, and α-synuclein mediated protein aggregation. These DA neurons derived from iPSCs from patients provide an in vitro tool to understand the complex interactions between human microglia and other cells such as astrocytes in 2D or 3D organoid systems to create more accurate models to mimic neurodegenerative diseases. The cells generated by this method can be utilized in disease modeling, drug discovery, and regenerative medicine.

[0050] In some embodiments, the DA neurons can be used for early diagnosis of PD using dopamine release assays or by measuring TH, DDC, MAOA, and COMT transcript and protein expression levels in neurons.Lysosomal enzyme glucocerebrosidase (GCase) activity assays can be used for both DA neurons from PD and Gaucher patients as early diagnostic tests and disease phenotypes for screening drugs and compounds, regardless of whether PD is familial or sporadic.α-synuclein aggregation and mitochondrial ROS levels can also be used as disease information for early diagnosis and screening drugs and compounds.

[0051] I. Definition As used herein, "a" or "an" may mean one or more. As used herein in the claims, when used in conjunction with the word "comprising," the words "a" or "an" may mean one or more.

[0052] Use of the term "or" in the claims is used to mean "and / or," unless expressly indicated to refer only to alternatives or where the alternatives are mutually exclusive, but the present disclosure supports a definition that refers only to alternatives and "and / or." As used herein, "another" can mean at least a second or more.

[0053] The term "essentially" should be understood to mean that a method or composition includes only certain steps or materials that do not materially affect the basic and novel characteristics of those methods and compositions.

[0054] As used herein, a composition or medium that is "substantially free" of a particular substance or ingredient contains less than 30%, less than 20%, less than 15%, more preferably less than 10%, even more preferably less than 5% or most preferably less than 1% of the substance or ingredient.

[0055] As used herein, the terms "substantially" or "approximately" may be applied to modify quantitative comparisons, values, measurements or other expressions that may vary to an acceptable degree without resulting in a change in the basic function to which they relate.

[0056] The term "about" generally means within the standard deviation of the stated value, as determined using standard analytical techniques to measure the stated value. The term may also be used to refer to plus or minus 5% of the stated value.

[0057] As used herein, "essentially free" with respect to a particular component is used herein to mean that none of the particular components are intentionally incorporated into the composition and / or are present only as contaminants or in trace amounts.Thus, the total amount of the particular component resulting from any unintentional contamination of the composition is well below 0.05%, preferably below 0.01%.Most preferred are compositions in which the amount of the particular component cannot be detected by standard analytical methods.

[0058] As used herein, a "cell line" is an established cell culture derived from a cell or set of cells of the same type that grows indefinitely under specific conditions. The cells of a cell line may contain a homogenous genetic makeup.

[0059] "Feeder-free" or "feeder-independent" is used herein to refer to cultures supplemented with cytokines and growth factors (e.g., TGFβ, bFGF, LIF, analogs or mimetics thereof) instead of a feeder cell layer. Thus, "feeder-free" or feeder-independent culture systems and media can be used to culture and maintain pluripotent cells in an undifferentiated and proliferative state. In some cases, feeder-free cultures utilize animal-based matrices (e.g., MATRIGEL™) or are cultured on substrates such as fibronectin, collagen, or vitronectin. These approaches allow human stem cells to be kept essentially undifferentiated without the need for a "feeder layer" of mouse fibroblasts.

[0060] A "feeder layer" is defined herein as a coating layer of cells, such as the bottom of a culture dish. Feeder cells can release nutrients into the medium and provide a surface to which other cells, such as pluripotent stem cells, can attach.

[0061] The term "defined" or "fully defined", when used in reference to a medium, extracellular matrix, or culture condition, refers to a medium, extracellular matrix, or culture condition in which the chemical composition and amount of nearly all components are known. For example, a defined medium does not contain undefined factors such as fetal bovine serum, bovine serum albumin, or human serum albumin. Generally, a defined medium includes a basal medium (e.g., Dulbecco's Modified Eagle Medium (DMEM), F12, or Roswell Park Memorial Institute Medium (RPMI) 1640, which contains amino acids, vitamins, inorganic salts, buffers, antioxidants, and energy sources) supplemented with recombinant albumin, lipids of known composition, and recombinant insulin. An example of a fully defined medium is Essential 8™ medium.

[0062] For media, extracellular matrices or culture systems used with human cells, the term "xeno-free (XF)" refers to the condition in which the materials used are not derived from non-human animals.

[0063] "Treatment" or "treating" includes (1) inhibiting a disease in a subject or patient experiencing or exhibiting symptoms or symptomology of a disease (e.g., arresting further development of the symptoms and / or symptomology), (2) ameliorating a disease in a subject or patient experiencing or exhibiting symptoms or symptomology of a disease (e.g., reversing the symptoms and / or symptomology), and / or (3) causing a measurable reduction in a disease in a subject or patient experiencing or exhibiting symptoms or symptomology of a disease.

[0064] "Prophylactic treatment" includes (1) reducing or alleviating the risk of developing a disease in a subject or patient who may be at risk and / or predisposed to the disease, but who has not yet experienced or displayed any or all of the symptoms or symptomatology of the disease, and / or (2) delaying the onset of symptoms or symptomatology of the disease in a subject or patient who may be at risk and / or predisposed to the disease, but who has not yet experienced or displayed any or all of the symptoms or symptomatology of the disease.

[0065] As used herein, the term "patient" or "subject" refers to a living mammal, such as a human, monkey, cow, sheep, goat, dog, cat, mouse, rat, guinea pig, or transgenic species thereof. In certain embodiments, the patient or subject is a primate. Non-limiting examples of human patients are adults, juveniles, infants, and fetuses.

[0066] The term "effective" as that term is used in the specification and / or claims means adequate to achieve a desired, expected or intended result. An "effective amount", "therapeutically effective amount" or "pharmacologically effective amount" when used in connection with treating a patient or subject with a compound means an amount of a compound that, when administered to a subject or patient for treating or preventing a disease, is an amount sufficient to affect the treatment or prevention of such disease.

[0067] Generally, as used herein, "pharmacologically acceptable" refers to those compounds, materials, compositions and / or dosage forms which are suitable, within the scope of sound medical judgment, for use in contact with the tissues, organs and / or body fluids of human beings and animals without undue toxicity, irritation, allergic response or other problem or complication commensurate with a reasonable benefit / risk ratio.

[0068] "Induced pluripotent stem cells (iPSCs)" are cells generated by reprogramming somatic cells through the expression or induction of expression of a combination of factors (referred to herein as reprogramming factors). iPSCs can be generated using fetal, postnatal, neonatal, juvenile or adult somatic cells. In certain embodiments, factors that can be used to reprogram somatic cells into pluripotent stem cells include, for example, Oct4 (sometimes referred to as Oct 3 / 4), Sox2, c-Myc, Klf4, Nanog and Lin28. In some embodiments, somatic cells are reprogrammed by expressing at least two reprogramming factors, at least three reprogramming factors, or four reprogramming factors to reprogram somatic cells into pluripotent stem cells.

[0069] The term "extracellular matrix protein" refers to molecules that provide structural and biochemical support to surrounding cells. Extracellular matrix proteins can be recombinant and also refer to fragments or peptides thereof. Examples include collagen and heparin sulfate.

[0070] "Adherent culture" refers to a culture in which cells or aggregates of cells attach to a surface.

[0071] "Suspension culture" refers to a culture in which cells or aggregates of cells grow in suspension in a liquid medium.

[0072] "Three-dimensional (3D) culture" refers to an artificially created environment in which biological cells can grow or interact with their surroundings in all three dimensions. 3D cultures can be grown in a variety of cell culture vessels, such as bioreactors, small capsules in which cells can grow into spheroids, or non-adherent culture plates. In certain embodiments, the 3D culture is scaffold-free. In contrast, "two-dimensional (2-D)" culture refers to cell culture, such as a monolayer on an adherent surface.

[0073] The term "aggregate-promoting medium" refers to any medium that enhances cellular aggregate formation without any limitation as to mechanism of action.

[0074] The term "aggregates", or embryoid bodies, refers to homogeneous or heterogeneous clusters of cells, including differentiated cells, partially differentiated cells, and / or pluripotent stem cells, cultured in suspension.

[0075] "Neurons" or "neuronal cells" or "neuronal cell types" or "neural lineage" may include any neuronal lineage cells and may be considered to refer to cells at any stage of neuronal ontogeny without any limitations unless otherwise specified. For example, neurons may include both neuronal progenitor cells and / or mature neurons. "Nervous system cells" or "nervous system cell types" and "nervous system lineage" cells may include any neuronal lineage and / or any stage of neuronal ontogeny without any limitations unless otherwise specified. For example, nervous system cells may include neuronal progenitor cells, glial progenitor cells, mature neurons, and / or glia.

[0076] As used herein, "mesencephalic DA neuron progenitor cells", "mDA neuron progenitor cells", and "mDA progenitor cells" are used interchangeably and refer to neuronal progenitor cells that express FoxA2, ​​Lmx1, and EN1 (mesencephalic specific markers); however, the cells do not express Nurr1. Mesencephalic DA neuron progenitor cells may express one or more of GBX2, OTX2, ETV5, DBX1TPH2, TH, BARHL1, SLC6A4, PITX3, PITX2, GATA2, NR4A2, GAD1, DCX, NXK6-1, RBFOX3, KCNJ6, CORIN, CD44, SPRY1, FABP7, SLC17A7, OTX1, and / or FGFR3. mDA progenitor cells may express selected genes at different stages of differentiation.

[0077] As used herein, the "disruption" of a gene refers to the elimination or reduction of expression of one or more gene products encoded by a gene of interest in a cell, compared to the expression level of the gene product in the absence of the disruption. Exemplary gene products include the mRNA and protein products encoded by the gene. The disruption may be temporary or reversible, or may be permanent. In some cases, the disruption is the disruption of a functional or full-length protein or mRNA, despite the fact that a truncated or non-functional product may be produced. In some embodiments herein, the activity or function of a gene is disrupted, as opposed to expression. Gene disruption is generally induced by artificial methods, i.e., the addition or introduction of a compound, molecule, complex or composition, and / or by disruption of the nucleic acid of the gene or the nucleic acid associated with the gene, such as at the DNA level. Exemplary methods of gene disruption include gene disruption techniques, such as gene silencing, knockdown, knockout, and / or gene editing. Examples include antisense technologies such as RNAi, siRNA, shRNA and / or ribozymes, which generally result in a transient reduction in expression and gene editing techniques that result in the inactivation or disruption of a targeted gene, for example by inducing truncation and / or homologous recombination. Examples include insertion, mutation and deletion. Disruption typically results in the suppression and / or complete absence of expression of the normal or "wild type" product encoded by the gene. Examples of such gene disruptions are insertions, frameshift and missense mutations, deletions, knock-ins and knock-outs of genes or parts of genes, including deletion of the entire gene. Such disruptions can occur in coding regions, for example in one or more exons, resulting in the inability to produce a full-length product, a functional product or any product, such as by the insertion of a stop codon. Such disruptions can also occur by disruption of promoters or enhancers or other regions that affect activation of transcription, to prevent transcription of the gene. Gene disruption includes gene targeting, including inactivation of a targeted gene by homologous recombination.

[0078] II. iPSC-derived dopaminergic neurons A. Pluripotent stem cells In certain embodiments, the present disclosure provides methods for differentiation of dopaminergic neurons from pluripotent stem cells, such as iPSCs. Differentiation can be performed by methods known in the art or by methods disclosed herein.

[0079] Theoretically, pluripotent stem cells can differentiate into any cell in the body, and experimental determination of pluripotency is typically based on differentiation of pluripotent cells into several cell types of each germ layer. In some embodiments, the pluripotent stem cells are embryonic stem (ES) cells derived from the inner cell mass of a blastocyst. In other embodiments, the pluripotent stem cells are induced pluripotent stem cells by reprogramming somatic cells. In some embodiments, the pluripotent stem cells are embryonic stem cells obtained by somatic cell nuclear transfer. The pluripotent stem cells can be obtained or derived from healthy subjects (e.g., healthy humans) or subjects with diseases (e.g., neurodegenerative diseases, Parkinson's disease, etc.).

[0080] Induced pluripotent stem (iPS) cells are cells with characteristics of ES cells, but obtained by reprogramming differentiated somatic cells. Induced pluripotent stem cells are obtained by various methods. In one method, adult human skin fibroblasts are transfected with the transcription factors Oct4, Sox2, c-Myc, and Klf4 using retroviral transduction (Takahashi et al., 2006, 2007). The transfected cells are plated on SNL feeder cells (a mouse cell fibroblast line that produces LIF) in medium supplemented with basic fibroblast growth factor (bFGF). After about 25 days, colonies resembling human ES cell colonies appear in the culture. The ES cell-like colonies are picked up and expanded on feeder cells in the presence of bFGF. In some preferred embodiments, the iPS cells are human iPS cells.

[0081] Based on the cell characteristics, the cells of the ES cell-like colonies are induced pluripotent stem cells. Induced pluripotent stem cells are morphologically similar to human ES cells and express various human ES cell markers. In addition, when grown under conditions known to result in the differentiation of human ES cells, induced pluripotent stem cells differentiate accordingly. For example, induced pluripotent stem cells can differentiate into cells with neuronal structures and neuronal markers. It is expected that virtually any iPS cell or cell line can be used with the present invention, including, for example, those described in Yu and Thomson, 2008.

[0082] In another method, human fetal or neonatal fibroblasts are transfected with four genes, Oct4, Sox2, Nanog, and Lin28, using lentiviral transduction (Yu et al., 2007). 12-20 days after infection, colonies with human ES cell morphology become visible. The colonies are picked up and expanded. The induced pluripotent stem cells that compose the colonies are morphologically similar to human ES cells, express various human ES cell markers, and form teratomas with neural tissue, cartilage, and intestinal epithelium after injection into mice.

[0083] Methods for preparing induced pluripotent stem cells from mouse cells are also known (Takahashi and Yamanaka, 2006). The induction of iPS cells typically requires the expression or exposure of at least one member of the Sox family and at least one member of the Oct family. Sox and Oct are believed to be central to the transcriptional regulatory hierarchy that specifies the identity of ES cells. For example, Sox can be Sox-1, Sox-2, Sox-3, Sox-15, or Sox-18; Oct can be Oct-4. Additional factors such as Nanog, Lin28, Klf4, or c-Myc can improve reprogramming efficiency; a particular set of reprogramming factors can include Sox-2, Oct-4, Nanog, and optionally Lin-28; or a set including Sox-2, Oct4, Klf, and optionally c-Myc.

[0084] Like ES cells, IPS cells have characteristic antigens that can be identified or confirmed by immunohistochemistry or flow cytometry using antibodies SSEA-1, SSEA-3, and SSEA-4 (Developmental Studies Hybridoma Bank, National Institute of Child Health and Human Development, Bethesda Md.), and TRA-1-60 and TRA-1-81 (Andrews et al., 1987). The pluripotency of embryonic stem cells can be confirmed, for example, by injecting approximately 0.5-10×10 cells into the hind leg muscles of 8-12 week-old male SCID mice. 6 This can be confirmed by injecting cells into the embryo, resulting in a teratoma that displays at least one cell type from each of the three germ layers.

[0085] In certain aspects of the invention, iPS cells are generated from reprogramming somatic cells with reprogramming factors including Oct family members and Sox family members, such as Oct4 and Sox2, in combination with Klf or Nanog, for example as described above. The somatic cells can be any somatic cells that can be induced to pluripotency, such as, for example, fibroblasts, keratinocytes, hematopoietic cells, mesenchymal cells, hepatocytes, gastric cells, or beta cells. In some embodiments, T cells can also be used as a source of somatic cells for reprogramming (see, for example, WO 2010 / 141801, incorporated herein by reference).

[0086] Reprogramming factors can be expressed from expression cassettes comprising one or more vectors, for example, integrating vectors, non-chromosomally integrated RNA viral vectors (see U.S. Application No. 13 / 054,022, incorporated herein by reference), or episomal vectors such as EBV element-based systems (see, for example, WO 2009 / 149233, incorporated herein by reference; Yu et al., 2009). In further embodiments, reprogramming proteins or RNAs (such as mRNA or miRNA) can be directly introduced into somatic cells by protein or RNA transfection (Yakubov et al., 2010).

[0087] Methods for the preparation and culture of pluripotent stem cells can be found in standard textbooks and reviews in cell biology, tissue culture, and development, including teratocarcinoma and embryonic stem cells: Guide to Techniques in Mouse Development (1993); Embryonic Stem Cell Differentiation in vitro (1993); Properties and uses of Embryonic Stem Cells: Prospects for Application to Human Biology and Gene Therapy (1998), all of which are incorporated herein by reference. Standard methods used in tissue culture are generally described in Animal Cell Culture (1987); Gene Transfer Vectors for Mammalian Cells (1987); and Current Protocols in Molecular Biology and Short Protocols in Molecular Biology (1987 & 1995).

[0088] After introducing or contacting the somatic cells with the reprogramming factors, these cells can be cultured in a medium sufficient to maintain pluripotency and an undifferentiated state. For the culture of induced pluripotent stem (iPS) cells, various media and techniques developed for culturing primate pluripotent stem cells, embryonic stem cells, or iPS cells, as described, for example, in US Patent Application Publication Nos. 2007 / 0238170, 2003 / 0211603, and 2008 / 0171385, which are incorporated herein by reference, can be used. It is contemplated that additional methods for culturing and maintaining pluripotent stem cells, which would be known to those skilled in the art, can be used with the present invention.

[0089] In certain embodiments, non-defined conditions can be used; for example, pluripotent cells can be cultured on fibroblast feeder cells or media exposed to fibroblast feeder cells to maintain the stem cells in an undifferentiated state. Alternatively, pluripotent cells can be cultured using defined feeder-independent culture systems such as TeSR medium (Ludwig et al., 2006a; Ludwig et al., 2006b) or E8 medium (Chen et al., 2011; International Application PCT / US2011 / 046796) and maintained in an essentially undifferentiated state. Feeder-independent culture systems and media can be used to culture and maintain pluripotent cells. These approaches allow human pluripotent stem cells to maintain an essentially undifferentiated state without the need for a mouse fibroblast "feeder layer." As described herein, various modifications can be made to these methods to reduce costs as desired.

[0090] A variety of matrix components can be used for the culture, maintenance, or differentiation of human pluripotent stem cells. For example, collagen IV, fibronectin, laminin, and vitronectin can be used in combination to coat culture surfaces as a means of providing a solid support for pluripotent cell growth, as described in Ludwig et al. (2006a; 2006b), the entire contents of which are incorporated herein by reference.

[0091] Matrigel™ can also be used to provide a substrate for cell culture and maintenance of human pluripotent stem cells. Matrigel™ is a gelatinous protein mixture secreted by mouse tumor cells and is commercially available from BD Biosciences (New Jersey, USA). This mixture resembles the complex extracellular environment found in many tissues and is used by cell biologists as a substrate for cell culture.

[0092] Methods can be provided for improving the neural differentiation efficiency (especially midbrain DA differentiation efficiency) of pluripotent stem cells. Differentiation of pluripotent stem cells can be induced in various ways, such as in attached colonies or by the formation of cell aggregates, such as in a low-adhesion environment where those aggregates are called embryoid bodies (EBs). Molecular and cellular morphogenetic signals and events within EBs mimic many aspects of the natural ontogeny of such cells in developing embryos. Methods for directing cells to differentiate into neurons are provided, for example, in US Patent Publication No. 2012 / 0276063, which is incorporated herein by reference. More detailed and specific protocols for differentiation of DA neurons are described in WO2013 / 067362, which is incorporated herein by reference.

[0093] Embryoid bodies (EBs) are aggregates of cells derived from pluripotent stem cells, such as ES cells or iPS cells, and have been studied for many years using mouse embryonic stem cells. Three-dimensional aggregates (i.e., embryoid bodies) can be generated as an intermediate step to recapitulate some of the cues inherent to in vivo differentiation. Once cell aggregation begins, differentiation can begin and cells can begin to recapitulate embryonic development to a limited extent. They cannot form trophectoderm tissues (including the placenta), but can give rise to virtually all other types of cells present in the organism. The present invention can further promote neural differentiation after aggregate formation.

[0094] Cell aggregation can be forced by plating into hanging drops, non-tissue culture treated plates or spinner flasks; both methods prevent the cells from attaching to the surface and forming typical colony growth. ROCK inhibitors or myosin II inhibitors can be used to culture pluripotent stem cells before, during or after aggregate formation.

[0095] Pluripotent stem cells can be seeded into aggregation-promoting medium using any method known in the art of cell culture. For example, pluripotent stem cells can be seeded into aggregation-promoting medium as single colonies or clonal groups, and pluripotent stem cells can also be seeded essentially as individual cells. In some embodiments, pluripotent stem cells are separated into essentially individual cells using mechanical or enzymatic methods known in the art. As a non-limiting example, pluripotent stem cells can be exposed to proteolytic enzymes that destroy the bonds between the cells and the culture surface and between the cells themselves. Enzymes that can be used to separate pluripotent stem cells for aggregate formation and differentiation can include, but are not limited to, trypsin, various commercial preparations thereof such as TrypLE, or mixtures of enzymes such as Accutase®. In certain embodiments, pluripotent cells can be added or seeded into culture medium for culture formation on a culture surface essentially as individual (or dispersed) cells.

[0096] For example, dispersed pluripotent cells can be seeded into culture medium. In these embodiments, the culture surface can be composed of essentially any material compatible with sterile cell culture methods standard in the art, e.g., a non-adherent surface. The culture surface can additionally include a matrix component as described herein. In some embodiments, the matrix component can be applied to the culture surface prior to contacting the surface with the cells and medium.

[0097] Substrates such as collagen, fibronectin, vitronectin, laminin, and matrigel can be used to induce differentiation. Differentiation can also be induced by leaving the cells in suspension in the presence of proliferation-inducing growth factors without reinitiating proliferation (i.e., without the neurospheres detaching).

[0098] In some embodiments, cells are cultured on a fixed substrate in a culture medium. A proliferation-inducing growth factor can then be administered to the cells. The proliferation-inducing growth factor can cause the cells to attach to the substrate (e.g., polyornithine-treated plastic or glass), flatten, and initiate differentiation into different cell types.

[0099] B. Dopaminergic neurons The dopaminergic neurons of the midbrain are the main source of dopamine (DA) in the mammalian central nervous system. Their loss is associated with Parkinson's disease (PD), one of the most prominent human neurological diseases. In some embodiments, dopaminergic neurons can be generated as described in WO2013067362; WO2013163228; WO2012080248; or WO2011130675.

[0100] In some embodiments, the following methods can be used to generate dopaminergic neurons from pluripotent stem cells, such as embryonic stem cells or iPS cells. For example, in some embodiments, the methods of US Patent Publication No. 2012 / 0276063 can be used to generate neurons from pluripotent stem cells. For example, in some embodiments, bFGF and TGFβ can be removed from the medium used to culture pluripotent cells, such as iPS cells, (e.g., from a defined medium, such as TeSR or Essential 8 medium) before the onset of aggregate formation (while the cells are still in adherent culture), and then used to promote neuronal differentiation of the pluripotent cells. In some embodiments, when iPS cells are "primed" in the absence of TeSR growth factors, i.e., cultured in any medium without basic fibroblast growth factor (bFGF) and transforming growth factor β (TGFβ), for several days before aggregate formation, the cells can develop into neural lineages with purity, rapidity, and consistency. Other methods for generating neurons include Zhang et al. (2013), U.S. Patent No. 7,820,439, WO 2011 / 091048, U.S. Patent Nos. 8,153,428, 8,252,586, and 8,426,200. In some embodiments, single or dual SMAD inhibition can be used to differentiate iPSCs into DA neurons.

[0101] In some embodiments, in a method of converting pluripotent cells (e.g., iPS cells, ES cells) into neural cells, such as midbrain dopaminergic cells, either a single BMP signaling inhibitor or a single TGF-β signaling inhibitor is used to inhibit SMAD signaling. For example, in some embodiments, pluripotent cells are converted into a population of neural cells, including midbrain DA neurons, and differentiation occurs in a medium containing a single BMP signaling inhibitor. In some embodiments, the BMP inhibitor is LDN-193189, dorsomorphin, or DMH-1. Non-limiting examples of inhibitors of BMP signaling include dorsomorphin, dominant negative BMP, truncated BMP receptor, soluble BMP receptor, BMP receptor-Fc chimera, noggin, LDN-193189, follistatin, chordin, gremlin, cerberus / DAN family proteins, ventropin, high-dose activin, and amnionless. In some embodiments, BMP signaling can be inhibited using nucleic acid, antisense, RNAi, siRNA, or other genetic methods. As used herein, BMP signaling inhibitors may simply refer to "BMP inhibitors." BMP inhibitors can be included in the differentiation medium on days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and / or 17 of differentiation, or any range derivable therein (e.g., days 1-17, days 1-16, days 1-15, days 2-15, etc.). In some embodiments, BMP inhibitors are included in the differentiation medium on all days 1-17 of differentiation. Nevertheless, it is anticipated that it may be possible to remove the BMP inhibitor from the differentiation medium at a particular time, for example, days 1, 2, or 3 of the above days. In some embodiments, the BMP inhibitor is optionally not included in the differentiation medium on days 11-17, and in some preferred embodiments, the BMP inhibitor is included in the differentiation medium on days 1-10.

[0102] In some embodiments, pluripotent cells are differentiated using the single SMAD method for a period of about 360-456 hours, more preferably about 384-432 hours, to generate a culture of neural cells. In the single SMAD method, a single SMAD inhibitor, such as a single BMP signaling inhibitor or a single TGF-β signaling inhibitor, is used to inhibit SMAD signaling in a method of converting pluripotent cells (e.g., iPS cells, ES cells) into neural cells, such as midbrain dopaminergic cells. Generally, in contrast to other dual SMAD differentiation methods, the single SMAD differentiation method utilizes only a single SMAD inhibitor, and a second SMAD inhibitor is not included in the differentiation medium. For example, in some embodiments, pluripotent cells are converted into a population of neuronal progenitor cells, including midbrain DA neuronal progenitor cells, and differentiation occurs in a medium containing a single BMP signaling inhibitor.

[0103] In some embodiments, the BMP inhibitor is LDN-193189, dorsomorphin, DMH-1, or noggin. For example, cells can be cultured in a medium containing about 1-2500, 1-2000, or 1-1,000 nM of LDN-193189 (e.g., about 10-500, 50-500, 50-300, 50, 100, 150, 200, 250, 300, 500, 750, 1000, 1250, 1500, 1750, 2000, 2250, or about 2500 nM of LDN-193189, or any range derivable therein). In some embodiments, the cells can be cultured in a medium containing about 0.1-10 μM dorsomorphin (e.g., about 0.1-10, 0.5-7.5, 0.75-5, 0.5-3, 1-3, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 2, 2.25, 2.5, 2.75, 3, or about 2 μM dorsomorphin, or any range derivable therein). In some embodiments, the cells can be cultured in a medium containing about 1 μM DMH-1 (e.g., about 0.2-8, 0.5-2, or about 1 μM DMH-1, or any range derivable therein). As shown in the Examples below, LDN-193189, dorsomorphin, and DMH-1 have all been successfully used in single SMAD inhibition approaches to generate midbrain dopaminergic neurons from iPS cells.

[0104] In some embodiments, a TGFβ inhibitor can be used as a single SMAD inhibitor to inhibit SMADs and generate midbrain dopaminergic neurons from pluripotent cells such as iPS cells. For example, in some embodiments, the differentiation medium comprises at least a first TGFβ signaling inhibitor. Non-limiting examples of inhibitors of TGFβ signaling include A-83-01, GW6604, IN-1130, K i26894, LY2157299, LY364947 (HTS-466284), A-83-01, LY550410, LY573636, LY580276, NPC-30345, SB-431542, SB-505124, SD-093, Sml6, SM305, SX-007, Antp-Sm2A, and LY2109761. For example, the TGFβ inhibitor in the differentiation medium can be SB431542. In some embodiments, the cells are cultured in a medium containing about 0.1-100 μM SB431542 (e.g., about 1-100 μM, 10-80 μM, 15-60 μM, 20-50 μM, or about 40 μM SB431542). As used herein, a TGFβ signaling inhibitor, including a TGFβ receptor inhibitor, can be simply referred to as a "TGFβ inhibitor." In some embodiments, a TGFβ inhibitor is not included in the differentiation medium. In some embodiments, a TGFβ inhibitor (e.g., SB431542) is included in the differentiation medium as a single SMAD inhibitor on days 1-3, or on days 1, 2, 3, and / or 4. As shown in the Examples below, in some embodiments, BMP inhibitors are used as the sole SMAD inhibitors because these compounds have been observed to result in superior differentiation of pluripotent cells into midbrain DA neurons compared to the use of TGFβ inhibitors.

[0105] In some aspects, a MEK inhibitor is included in the differentiation medium to generate midbrain dopaminergic neurons from pluripotent cells such as iPS cells, for example in combination with a BMP inhibitor or a single SMAD inhibitor. In some embodiments, the MEK inhibitor is PD0325901. Non-limiting examples of MEK inhibitors that can be used include PD0325901, trametinib (GSK1120212), selumetinib (AZD6244), pimasertib (AS-703026), MEK162, cobimetinib, PD184352, PD173074, BIX02189, AZD8330, and PD98059. For example, in some embodiments, the method includes culturing the cells in the presence of about 0.1-10 μM (e.g., about 0.1-5, 0.5-3, or 0.5-1.5 μM) of a MEK inhibitor, such as PD0325901. In some embodiments, the cells are contacted with the MEK inhibitor (e.g., PD0325901) on day 3, day 4, day 5, or day 3-5 of differentiation.

[0106] In some embodiments, mesencephalic DA neuron progenitor cells can be generated by a method including: obtaining a population of pluripotent cells; differentiating the cells into a neural lineage cell population in a medium containing a MEK inhibitor (e.g., PD0325901), where the medium does not contain exogenously added FGF8b on day 1 of differentiation; and further differentiating the cells of the neural lineage cell population to provide an enriched population of mesencephalic DA neurons. In some embodiments, it has been observed that including FGF8 (e.g., FGF8b) in the differentiation medium on day 1 can inhibit or prevent differentiation of cells into mesencephalic DA neuron progenitor cells in some instances. In some embodiments, FGF8 can be optionally included in the differentiation medium after, for example, 9, 10, 11, 12, 13, 14, 15, 16, 17 days of differentiation, or any range derivable therein. For example, preferably, contacting of pluripotent cells is initiated on day 1 with a single SMAD inhibitor in the differentiation medium.

[0107] In some embodiments, a Wnt activator (e.g., a GSK3 inhibitor) is included in the differentiation medium in combination with, for example, a BMP inhibitor or a single SMAD inhibitor, to generate midbrain dopaminergic neuron progenitor cells from pluripotent cells such as iPS cells. In some embodiments, the pluripotent cells are differentiated into a population of neural cells that include midbrain DA neurons, the differentiation being in a medium that includes at least a first activator of Wnt signaling.

[0108] Various Wnt activators or GSK3 inhibitors can be used in various aspects of the present disclosure. For example, the activator of WNT signaling can be a glycogen synthase kinase 3 (GSK3) inhibitor. Non-limiting examples of GSK3 inhibitors include NP031112, TWS119, SB216763, CHIR-98014, AZD2858, AZD1080, SB415286, LY2090314, and CHIR99021. In some embodiments, the pluripotent cells are contacted with a single SMAD inhibitor that is not SB415286. In some embodiments, the activator of Wnt signaling is CHIR99021. Thus, in some aspects, media for use according to the embodiments include about 0.1 to about 10 μM CHIR99021 (e.g., about 0.1 to 5, 0.5 to 5, 0.5 to 3, greater than about 1.25 to 2.25, about 1.25, 1.5, 1.55, 1.65, 1.7, 1.75, 1.8, 1.9, 2.0, or about 1.75 μM CHIR99021, or any range derivable therein). In some preferred embodiments, about 1.6 to 1.7 μM or about 1.65 μM CHIR99021 is used.

[0109] In some embodiments, an activator of Sonic Hedgehog (SHH) signaling is included in the differentiation medium, for example in combination with a BMP inhibitor or a single SMAD inhibitor, to generate midbrain dopaminergic neurons from pluripotent cells such as iPS cells. In some embodiments, the Sonic Hedgehog activator is Sonic Hedgehog (Shh) or a mutant Shh. Shh can be, for example, a human or mouse protein or can be derived from human or mouse Shh. For example, in some embodiments, Shh is a mutant mouse Shh protein, such as mouse C25II Shh or human C24II Shh. In some embodiments, the differentiation medium includes both Shh (e.g., C25II Shh) and a small molecule activator of SHH, such as purmorphamine. Without wishing to be bound by any theory, Shh and / or activators of Sonic Hedgehog can promote differentiation of the neural floor plate.

[0110] Cultures of neural cell types derived from pluripotent cells, including iPS cells, are also commercially available and can be purchased. For example, iCell® Neurons, iCell® DopaNeurons, and iCell® Astrocytes are derived from human iPS cells and can be purchased from Cellular Dynamics International (Madison, Wisconsin). iCell® Neurons are neurons derived from human induced pluripotent stem cells (iPSCs) and exhibit biochemical, electrophysiological, and pathophysiological properties characteristic of native human neurons. The high purity, functional relevance, and ease of use of iCell® Neurons make them an extremely useful in vitro test system for investigating neurobiology in many areas of basic research and drug development.

[0111] In some embodiments, defined media (i.e., media that does not contain tissue, feeder cells, or cell-conditioned media) can be used to generate neurons or astrocytes from pluripotent cells such as iPS cells.

[0112] Neural cells can be characterized according to several phenotypic criteria, including, but not limited to, microscopic observation of morphological features, detection or quantification of expressed cellular markers, enzymatic activity, neurotransmitters and their receptors, and electrophysiological function.

[0113] In some embodiments, the model can be provided in a microfluidic device. Various microfluidic device configurations useful for supporting cells are known in the art, including in the form of an in vitro vascular model. See, for example, US Patent Application Publication No. 2011 / 0053207 and US Patent Application Publication No. 2014 / 0038279, which are incorporated herein by reference. In general, a microfluidic device including a blood-brain barrier model as taught herein can include a chamber dimensioned to receive the blood-brain barrier model therein, such that the endothelial cell layer and the neuronal cell layer define a boundary between a first chamber or opening in fluid contact with the endothelial cell layer of the model and a second chamber or opening in fluid contact with the neuronal cell layer of the model. The fluid can be a liquid, such as a medium or buffer. The device can further include a fluid inlet and a fluid outlet for each chamber, a fluid reservoir (e.g., a medium reservoir) connected thereto, and the like.

[0114] In some embodiments, the cells used in cell culture are generated from iPS cells generated from cells obtained from a healthy donor. In other embodiments, the donor has a disease. For example, in some embodiments, the donor has a disease, such as a neurological or neurodegenerative disease, such as epilepsy, autism, attention deficit hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth (CMT), Huntington's disease, familial epilepsy, schizophrenia, familial Alzheimer's disease, Friedreich's ataxia, spinocerebellar ataxia, spinal muscular atrophy, hereditary spastic paraparesis, leukodystrophy, phenylketonuria, Tay-Sachs disease, Wilson's disease, addiction disorder, depression, or mood disorder. The disease can be a genetic disease or an increased genetic susceptibility to a particular neurological disease. Additionally, provided herein is an assay for studying neuroinflammation using the present cell culture models.

[0115] Cells are generally seeded in suitable culture vessels such as flasks, tissue culture plates such as 6-well, 24-well, or 96-well plates. Culture vessels used to culture cells may include, but are not limited to: flasks, tissue culture flasks, dishes, Petri dishes, tissue culture dishes, multi-dishes, microplates, microwell plates, multi-plates, multiwell plates, microslides, chamber slides, tubes, trays, CELLSTACK® chambers, culture bags, and roller bottles, provided that stem cells can be cultured therein. Cells may be cultured in volumes of at least or about 0.2, 0.5, 1, 2, 5, 10, 20, 30, 40, 50 ml, 100 ml, 150 ml, 200 ml, 250 ml, 300 ml, 350 ml, 400 ml, 450 ml, 500 ml, 550 ml, 600 ml, 800 ml, 1000 ml, 1500 ml, or any range of volumes derivable therein, depending on the needs of the culture. In certain embodiments, the culture vessel may be a bioreactor, which may refer to any ex vivo device or system that supports a biologically active environment for cells to grow in. The bioreactor may have a volume of at least or about 2, 4, 5, 6, 8, 10, 15, 20, 25, 50, 75, 100, 150, 200, 500 liters, 1, 2, 4, 6, 8, 10, 15 cubic meters, or any range derivable therein.

[0116] C. Gene Disruption In certain aspects, the expression, activity or function of the SNCA, GBA or LRRK2 gene is disrupted in cells such as PSCs (e.g., ESCs or iPSCs). In some embodiments, gene disruption is carried out by causing disruption of the gene, such as knockout, insertion, frameshift mutation such as missense or biallelic frameshift mutation, deletion and / or knock-in of all or part of the gene, such as one or more exons or parts thereof. For example, disruption can be performed by sequence-specific or targeted nucleases, including DNA-binding targeted nucleases such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) and RNA-guided nucleases such as CRISPR-associated nucleases (Cas), which are specifically designed to target the sequence of a gene or part thereof.

[0117] In some embodiments, disruption of gene expression, activity and / or function is carried out by disrupting the gene. In some embodiments, the gene is disrupted such that its expression is reduced by at least or about 20, 30 or 40%, typically at least or about 50, 60, 70, 80, 90 or 95%, compared to its expression in the absence of the gene disruption or in the absence of components introduced to effect the disruption.

[0118] In some embodiments, the disruption is transient or reversible, such that expression of the gene is subsequently restored, in other embodiments, the disruption is not reversible or transient, e.g., permanent.

[0119] In some embodiments, gene disruption is typically performed by inducing one or more double-strand breaks and / or one or more single-strand breaks in a gene in a targeted manner.In some embodiments, double-strand or single-strand breaks are performed by a nuclease, for example an endonuclease, such as a gene-targeting nuclease.In some aspects, the break is induced in the coding region of a gene, for example an exon.For example, in some embodiments, the induction occurs near the N-terminal part of the coding region, for example the first exon, the second exon or a subsequent exon.

[0120] In some embodiments, double-stranded or single-stranded breaks undergo repair through cellular repair processes, such as by non-homologous end joining (NHEJ) or homology-directed repair (HDR). In some embodiments, the repair process is error-prone, resulting in disruption of the gene, such as a frameshift mutation, e.g., a biallelic frameshift mutation, which may result in a complete knockout of the gene. For example, in some embodiments, the disruption includes inducing a deletion, mutation, and / or insertion. In some embodiments, the disruption results in the presence of a premature stop codon. In some embodiments, the insertion, deletion, translocation, frameshift mutation, and / or the presence of a premature stop codon results in disruption of the expression, activity, and / or function of the gene.

[0121] In some embodiments, gene disruption is achieved using antisense technology, such as RNA interference (RNAi), short interfering RNA (siRNA), short hairpin (shRNA) and / or ribozymes, to selectively suppress or block the expression of a gene. siRNA technology is RNAi using a double-stranded RNA molecule that has a sequence that is homologous to the nucleotide sequence of the mRNA transcribed from the gene and a sequence that is complementary to the nucleotide sequence. siRNAs can generally be siRNAs that contain multiple RNA molecules that are homologous / complementary to one region of the mRNA transcribed from the gene or homologous / complementary to different regions. In some embodiments, siRNAs are included in polycistronic constructs. In certain embodiments, siRNAs suppress both wild-type and mutant protein translation from endogenous mRNA.

[0122] In some embodiments, the disruption is achieved using a DNA targeting molecule, such as a DNA binding protein or a DNA binding nucleic acid, or a complex, compound, or composition comprising the same, that specifically binds or hybridizes to the gene. In some embodiments, the DNA targeting molecule comprises a DNA binding domain, such as a zinc finger protein (ZFP) DNA binding domain, a transcription activator-like protein (TAL) or TAL effector (TALE) DNA binding domain, a clustered regularly interspaced short palindromic repeats (CRISPR) DNA binding domain, or a DNA binding domain from a meganuclease. Zinc finger, TALE, and CRISPR system binding domains can be engineered to bind to a given nucleotide sequence, for example, through engineering (changing one or more amino acids) of the recognition helix region of a naturally occurring zinc finger or TALE protein. Engineered DNA binding proteins (zinc finger or TALE) are non-naturally occurring proteins. Rational criteria for design include the application of substitution rules and computerized algorithms to process information in databases that store information and binding data of existing ZFP and / or TALE designs. See, e.g., U.S. Patent Nos. 6,140,081; 6,453,242; and 6,534,261. See also WO 98 / 53058; WO 98 / 53059; WO 98 / 53060; WO 02 / 016536 and WO 03 / 016496, and U.S. Patent Application Publication No. 2011 / 0301073.

[0123] In some embodiments, the DNA targeting molecule, complex or combination comprises a DNA binding molecule and one or more additional domains, such as an effector domain for promoting gene suppression or destruction.For example, in some embodiments, gene destruction is carried out by a fusion protein comprising a DNA binding protein and a heterologous regulatory domain or a functional fragment thereof.In some embodiments, the domain comprises a transcription factor domain, such as activator, repressor, coactivator, corepressor, silencer, oncogene, DNA repair enzymes and their associated factors and modifiers, DNA rearrangement enzymes and their associated factors and modifiers, chromatin-associated proteins and their modifiers, such as kinases, acetylases and deacetylases, and DNA modifying enzymes, such as methyltransferases, topoisomerases, helicases, ligases, kinases, phosphatases, polymerases, endonucleases and their associated factors and modifiers. For details on the fusion of DNA binding domain and nuclease cleavage domain, see, for example, US Patent Application Publication Nos. 2005 / 0064474; 2006 / 0188987 and 2007 / 0218528, which are incorporated herein by reference in their entirety.In some embodiments, the additional domain is a nuclease domain.Thus, in some embodiments, gene disruption is facilitated by gene or genome editing using engineered proteins such as nucleases and nuclease-containing complexes or fusion proteins, which are composed of sequence-specific DNA binding domains fused or complexed with non-specific DNA cleavage molecules such as nucleases.

[0124] In some embodiments, these targeted chimeric nucleases or nuclease-containing complexes induce targeted double-strand or single-strand breaks and perform precise genetic modification by stimulating cellular DNA repair mechanisms, including error-prone non-homologous end joining (NHEJ) and homology-directed repair (HDR). In some embodiments, the nuclease is an endonucleases such as zinc finger nucleases (ZFNs), TALE nucleases (TALENs), and RNA-guided endonucleases (RGENs) or meganucleases such as CRISPR-associated (Cas) proteins.

[0125] In some embodiments, a donor nucleic acid, such as a donor plasmid or a nucleic acid encoding an engineered antigen receptor, is provided and inserted by HDR at the site of gene editing following introduction of a DSB. Thus, in some embodiments, gene disruption and introduction of an antigen receptor, such as a CAR, are performed simultaneously, whereby the gene is partially disrupted by knock-in or insertion of a nucleic acid encoding a CAR.

[0126] In some embodiments, no donor nucleic acid is provided. In some embodiments, NHEJ-mediated repair following introduction of a DSB results in an insertion or deletion mutation that can cause gene disruption, for example, by creating a missense mutation or a frameshift.

[0127] 1. ZFPs and ZFNs In some embodiments, the DNA targeting molecule comprises a DNA binding protein, such as one or more zinc finger proteins (ZFPs) or transcription activator-like proteins (TALs), fused to an effector protein, such as an endonuclease. Examples include ZFNs, TALEs, and TALENs.

[0128] In some embodiments, the DNA targeting molecule comprises one or more zinc finger proteins (ZFPs) or domains thereof that bind to DNA in a sequence-specific manner. A ZFP or domain thereof is a protein or domain within a larger protein that binds to DNA in a sequence-specific manner via one or more zinc fingers, a region of amino acid sequence within the binding domain, the structure of which is stabilized by the coordination of a zinc ion. The term zinc finger DNA binding protein is often abbreviated as zinc finger protein or ZFP. Among the ZFPs are artificial ZFP domains that target specific DNA sequences, typically 9-18 nucleotides long, generated by assembly of individual fingers.

[0129] ZFPs include those in which the single finger domain is approximately 30 amino acids long, contains two invariant histidine residues coordinated through zinc to two cysteines in a single beta turn, and contains an alpha helix with two, three, four, five, or six fingers. In general, the sequence specificity of ZFPs can be altered by making amino acid substitutions at the four helical positions (-1, 2, 3, and 6) of the zinc finger recognition helix. Thus, in some embodiments, ZFPs or ZFP-containing molecules are engineered to bind to non-natural, e.g., selected, target sites.

[0130] In some embodiments, disruption of SNCA is carried out by contacting a first target site of the gene with a first ZFP, thereby disrupting the gene, hi some embodiments, the target site of the gene is contacted with a fusion ZFP comprising six fingers and a regulatory domain, thereby inhibiting expression of the gene.

[0131] In some embodiments, the contacting step further comprises contacting a second target site in the gene with a second ZFP. In some embodiments, the first and second target sites are adjacent. In some embodiments, the first and second ZFPs are covalently linked. In some embodiments, the first ZFP is a fusion protein comprising a regulatory domain or at least two regulatory domains.

[0132] In some embodiments, the first and second ZFPs each comprise a regulatory domain or are fusion proteins each comprising at least two regulatory domains, hi some embodiments, the regulatory domains are transcriptional repressors, transcriptional activators, endonucleases, methyltransferases, histone acetyltransferases, or histone deacetylases.

[0133] In some embodiments, the ZFP is encoded by a ZFP nucleic acid operably linked to a promoter. In some aspects, the method further comprises initially administering the nucleic acid to the cell in a lipid:nucleic acid complex or as a naked nucleic acid. In some embodiments, the ZFP is encoded by an expression vector comprising a ZFP nucleic acid operably linked to a promoter. In some embodiments, the ZFP is encoded by a nucleic acid operably linked to an inducible promoter. In some aspects, the ZFP is encoded by a nucleic acid operably linked to a weak promoter.

[0134] In some embodiments, the target site is upstream of the transcription start site of the gene. In some embodiments, the target site is adjacent to the transcription start site of the gene. In some embodiments, the target site is adjacent to an RNA polymerase pause site downstream of the transcription start site of the gene.

[0135] In some embodiments, the DNA targeting molecule is or comprises a zinc finger DNA binding domain fused to a DNA cleavage domain to form a zinc finger nuclease (ZFN). In some embodiments, the fusion protein comprises a cleavage domain (or cleavage half-domain) from at least one type liS restriction enzyme and one or more zinc finger binding domains, which may or may not be engineered. In some embodiments, the cleavage domain is derived from the type liS restriction endonuclease Fok I. Fok I catalyzes double-stranded cleavage of DNA, typically 9 nucleotides from the recognition site on one strand and 13 nucleotides from the recognition site on the other strand.

[0136] In some embodiments, ZFN targets genes present in engineered cells. In some aspects, ZFN efficiently generates double-strand breaks (DSBs) at predetermined sites in the coding region of genes, for example. Typical regions targeted include exons, regions encoding N-terminal regions, first exons, second exons, and promoter or enhancer regions. In some embodiments, transient expression of ZFNs promotes highly efficient and permanent destruction of target genes in engineered cells. Notably, in some embodiments, delivery of ZFNs results in permanent destruction of genes with efficiency of over 50%.

[0137] Many gene-specific engineered zinc fingers are commercially available. For example, Sangamo Biosciences (Richmond, CA, USA) in collaboration with Sigma-Aldrich (St. Louis, MO, USA) has developed a platform for zinc finger construction (CompoZr) that allows researchers to bypass zinc finger construction and validation altogether and provides zinc fingers specifically targeted to thousands of proteins (Gaj et al., Trends in Biotechnology, 2013, 31(7), 397-405). In some embodiments, commercially available zinc fingers are used or custom designed.

[0138] 2. TAL, TALE and TALEN In some embodiments, the DNA targeting molecule comprises a naturally occurring or engineered (non-naturally occurring) transcription activator-like protein (TAL) DNA binding domain, such as a transcription activator-like protein effector (TALE) protein, see, e.g., U.S. Patent Application Publication No. 2011 / 0301073, which is incorporated herein by reference in its entirety.

[0139] A TALE DNA binding domain or TALE is a polypeptide that contains one or more TALE repeat domains / units. The repeat domains are responsible for binding of the TALE to its cognate target DNA sequence. A single "repeat unit" (also called "repeat") is typically 33-35 amino acids long and exhibits at least some sequence homology with other TALE repeat sequences in naturally occurring TALE proteins. Each TALE repeat unit typically contains one or two DNA binding residues at positions 12 and / or 13 of the repeat that constitute a repeat variable dipeptide (RVD). The natural (canonical) code for DNA recognition of these TALEs has been determined such that the HD sequence at positions 12 and 13 binds to cytosine (C), NG binds to T, NI binds to A, NN binds to G or A, and NO binds to T, and non-canonical (non-classical) RVDs are also known. See US Patent Application Publication No. 2011 / 0301073. In some embodiments, TALEs can target any gene by designing the TAL array with specificity for the target DNA sequence. The target sequence generally begins with a thymidine.

[0140] In some embodiments, the molecule is a DNA-binding endonuclease, such as a TALE nuclease (TALEN). In some embodiments, a TALEN is a fusion protein comprising a DNA-binding domain derived from a TALE and a nuclease catalytic domain for cleaving a nucleic acid target sequence.

[0141] In some embodiments, TALENs recognize and cleave target sequences in genes. In some embodiments, DNA cleavage results in double-strand breaks. In some embodiments, cleavage stimulates the rate of homologous recombination or non-homologous end joining (NHEJ). In general, NHEJ is an imperfect repair process that often leads to changes in DNA sequence at the cleavage site. In some embodiments, the repair mechanism involves rejoining the remains of the two DNA ends via direct religation (Critchlow and Jackson, 1998) or so-called microhomology-mediated end joining. In some embodiments, NHEJ-mediated repair results in small insertions or deletions that can be used to disrupt and thereby silence genes. In some embodiments, the modification can be a substitution, deletion or addition of at least one nucleotide. In some embodiments, cells in which a cleavage-induced mutagenesis event, i.e., a mutagenesis event subsequent to an NHEJ event, has occurred can be identified and / or selected by methods well known in the art.

[0142] In some embodiments, TALE repeats are assembled to specifically target genes. A library of TALENs targeting 18,740 human protein-coding genes has been constructed. Custom-designed TALE arrays are commercially available from Cellectis Bioresearch (Paris, France), Transposagen Biopharmaceuticals (Lexington, KY, USA) and Life Technologies (Grand Island, NY, USA).

[0143] In some embodiments, the TALENs are introduced as transgenes encoded by one or more plasmid vectors. In some embodiments, the plasmid vectors may contain a selection marker that provides for identification and / or selection of cells that have received the vector.

[0144] 3. RGEN (CRISPR / Cas system) In some embodiments, the disruption is carried out using one or more DNA-binding nucleic acids, such as RNA-guided endonuclease (RGEN)-mediated disruption. For example, the disruption can be carried out using clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins. In general, "CRISPR system" refers collectively to the transcripts and other elements involved in the expression or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding Cas genes, tracr (trans-activating CRISPR) sequences (e.g., tracrRNA or active partial tracrRNA), tracr-mate sequences (including "direct repeats" and tracrRNA-processed partial direct repeats in the context of endogenous CRISPR systems), guide sequences (also referred to as "spacers" in the context of endogenous CRISPR systems), and / or other sequences and transcripts from the CRISPR locus.

[0145] A CRISPR / Cas nuclease or CRISPR / Cas nuclease system can include a non-coding RNA molecule (guide) RNA that binds to DNA in a sequence-specific manner and a Cas protein (e.g., Cas9) with nuclease function (e.g., two nuclease domains). One or more elements of the CRISPR system can be derived from a Type I, Type II, or Type III CRISPR system, and can be derived from a particular organism that contains an endogenous CRISPR system, such as Streptococcus pyogenes.

[0146] In some embodiments, a Cas nuclease and a gRNA (comprising a fusion of a crRNA and an immobilized tracrRNA specific for a target sequence) are introduced into a cell. Generally, a target site at the 5' end of the gRNA allows the Cas nuclease to target a target site, e.g., a gene, using complementary base pairing. The target site can typically be selected based on the location directly 5' of a protospacer adjacent motif (PAM) sequence, such as NGG or NAG. In this regard, the gRNA targets a desired sequence by modifying the first 20, 19, 18, 17, 16, 15, 14, 14, 12, 11, or 10 nucleotides of the guide RNA to correspond to the target DNA sequence. In general, CRISPR systems are characterized by elements that promote the formation of a CRISPR complex at the site of the target sequence. Typically, a "target sequence" generally refers to a sequence to which the guide sequence is designed to have complementarity, and hybridization between the target sequence and the guide sequence promotes the formation of a CRISPR complex. Absolute complementarity is not required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex.

[0147] The CRISPR system can induce a double-strand break (DSB) at the target site, followed by disruption as described herein. In other embodiments, a Cas9 variant considered a "nickase" is used to nick a single strand at the target site. Paired nickases can be used, for example, to improve specificity, each directed by a pair of different gRNAs targeting sequences such that simultaneous introduction of a nick introduces a 5' overhang. In other embodiments, catalytically inactive Cas9 is fused to a heterologous effector domain, such as a transcriptional repressor or activator, to affect gene expression.

[0148] The target sequence may comprise any polynucleotide, such as a DNA or RNA polynucleotide. The target sequence may be located in the nucleus or cytoplasm of a cell, such as within an organelle of a cell. In general, a sequence or template that can be used for recombination into a target locus that comprises a target sequence is referred to as an "editing template", or an "editing polynucleotide", or an "editing sequence". In some embodiments, an exogenous template polynucleotide may be referred to as an editing template. In some embodiments, the recombination is a homologous recombination.

[0149] Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (including a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands within or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs therefrom). A tracr sequence that may include or consist of all or a portion of a wild-type tracr sequence (e.g., about 20 or more, about 26 or more, about 32 or more, about 45 or more, about 48 or more, about 54 or more, about 63 or more, about 67 or more, about 85 or more or more nucleotides of a wild-type tracr sequence) may form part of a CRISPR complex, such as by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence operably linked to a guide sequence. The tracr sequence has sufficient complementarity to the tracr mate sequence to hybridize and participate in the formation of a CRISPR complex (such as at least 50%, 60%, 70%, 80%, 90%, 95% or 99% sequence complementarity along the length of the tracr mate sequence when optimally aligned).

[0150] One or more vectors driving the expression of one or more elements of the CRISPR system can be introduced into a cell such that the expression of the elements of the CRISPR system directs the formation of a CRISPR complex at one or more target sites. The components can also be delivered to the cell as proteins and / or RNA. For example, the Cas enzyme, the guide sequence linked to the tracr-mate sequence, and the tracr sequence can each be operably linked to separate regulatory elements on separate vectors. Alternatively, two or more elements expressed from the same or different regulatory elements can be combined into a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. The vector can include one or more insertion sites, such as restriction endonuclease recognition sequences (also called "cloning sites"). In some embodiments, the one or more insertion sites are located upstream and / or downstream of one or more sequence elements of the one or more vectors. When multiple different guide sequences are used, a single expression construct can be used to target CRISPR activity to multiple different corresponding target sequences in a cell.

[0151] The vector can include regulatory elements operably linked to an enzyme coding sequence that encodes a CRISPR enzyme, such as a Cas protein. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof or modified versions thereof. These enzymes are known; for example, the amino acid sequence of the S. pyogenes Cas9 protein can be found in the SwissProt database under accession number Q99ZW2.

[0152] The CRISPR enzyme can be Cas9 (e.g., from S. pyogenes or S. pneumonia). The CRISPR enzyme can direct cleavage of one or both strands at the location of a target sequence, such as within the target sequence and / or within the complement of the target sequence. The vector can encode a CRISPR enzyme that is mutated with respect to the corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide that contains the target sequence. For example, an aspartic acid to alanine substitution (D10A) in the RuvC I catalytic domain of S. pyogenes Cas9 converts Cas9 from a nuclease that cleaves both strands to a nickase (that cleaves a single strand). In some embodiments, the Cas9 nickase can be used in combination with a guide sequence, e.g., two guide sequences that target the sense and antisense strands of a DNA target, respectively. This combination nicks both strands and can be used to induce NHEJ or HDR.

[0153] In some embodiments, the enzyme coding sequence encoding the CRISPR enzyme is codon-optimized for expression in a particular cell, such as a eukaryotic cell. The eukaryotic cell may be of or derived from a particular organism, such as a mammal, including but not limited to a human, mouse, rat, rabbit, dog, or non-human primate. In general, codon optimization refers to the process of modifying a nucleic acid sequence to enhance expression in a host cell of interest by replacing at least one codon of the native sequence with a codon that is more or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Different species show a particular bias for a particular codon of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the translation efficiency of messenger RNA (mRNA), which is believed to depend, among other things, on the properties of the codon being translated and the availability of a particular transfer RNA (tRNA) molecule. The dominance of the selected tRNA in a cell generally reflects the codon that is most frequently used in peptide synthesis. Thus, a gene can be tuned for optimal gene expression in a given organism based on codon optimization.

[0154] In general, a guide sequence is any polynucleotide sequence that has sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence is about 50% or more, about 60% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 97.5% or more, about 99% or more, or more, when optimally aligned using a suitable alignment algorithm.

[0155] Optimal alignment may be determined using any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler transformation (e.g., Burrows Wheeler Aligner), Clustal W, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).

[0156] CRISPR enzymes can be part of fusion proteins that contain one or more heterologous protein domains. CRISPR enzyme fusion proteins can contain any additional protein sequences and optionally linker sequences between any two domains. Examples of protein domains that can be fused to CRISPR enzymes include, but are not limited to, epitope tags, reporter gene sequences, and protein domains that have one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity, and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tag, V5 tag, FLAG tag, influenza hemagglutinin (HA) tag, Myc tag, VSV-G tag, and thioredoxin (Trx) tag. Examples of reporter genes include, but are not limited to, glutathione-5-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), autofluorescent proteins including HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP) and blue fluorescent protein (BFP). CRISPR enzymes may be fused to genetic sequences that encode proteins or fragments of proteins that bind to DNA molecules or other cellular molecules, including, but not limited to, maltose binding protein (MBP), S-tags, Lex A DNA binding domain (DBD) fusions, GAL4A DNA binding domain fusions and herpes simplex virus (HSV) BP16 protein fusions.

[0157] D. Differentiation medium The cells can be cultured with nutrients necessary to support the growth of each particular population of cells. Generally, the cells are cultured in a growth medium that includes a carbon source, a nitrogen source, and a buffer to maintain pH. The medium can also include fatty acids or lipids, amino acids (such as non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, pyruvate, buffering agents, pH indicators, and inorganic salts. Exemplary growth media include minimal essential media, such as Dulbecco's Modified Eagle Medium (DMEM) or ESSENTIAL 8™ (E8™) medium, supplemented with various nutrients, such as non-essential amino acids and vitamins, to enhance the growth of stem cells. Examples of minimal essential media include, but are not limited to, Minimum Essential Medium Eagle (MEM) Alpha Medium, Dulbecco's Modified Eagle Medium (DMEM), RPMI-1640 Medium, 199 Medium, and F12 Medium. Additionally, the minimal essential medium can be supplemented with additives such as horse, calf, or fetal bovine serum. Alternatively, the medium can be serum-free. In other cases, the growth medium may include "Knockout serum replacement," referred to herein as a serum-free formulation optimized to grow and maintain undifferentiated cells, such as stem cells, in culture. KNOCKOUT™ serum replacement is disclosed, for example, in U.S. Patent Application Publication No. 2002 / 0076747, which is incorporated herein by reference. Preferably, PSCs are cultured in a feeder-free, completely defined medium.

[0158] In some embodiments, the medium may or may not contain any substitute for serum. Serum substitutes may include materials that suitably contain albumin (lipid-rich albumin, albumin substitutes such as recombinant albumin, vegetable starch, dextran and protein hydrolysates), transferrin (or other iron transporters), fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thioglycerol or equivalents. Serum substitutes may be prepared, for example, by the methods disclosed in WO 98 / 30679. Alternatively, and more conveniently, commercially available materials may be used. Commercially available materials include KNOCKOUT™ serum substitute (KSR), lipid concentrates of known composition (Gibco) and GLUTAMAX™ (Gibco).

[0159] Other culture conditions can be appropriately defined. For example, the culture temperature can be about 30 to 40°C, for example, at least or about 31, 32, 33, 34, 35, 36, 37, 38, 39°C, but is not particularly limited thereto. In one embodiment, the cells are cultured at 37°C. The CO2 concentration can be about 1 to 10%, for example, about 2 to 5%, or any range derivable therein. The oxygen partial pressure can be at least up to or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20%, or any range derivable therein.

[0160] The differentiation medium according to certain aspects of the present disclosure can be prepared using a medium used for culturing animal cells as its base medium. In some embodiments, the differentiation medium is used to differentiate pluripotent cells into midbrain dopaminergic neuron precursor cells (e.g., D17 cells) using only a single BMP inhibitor or a single TGF-β inhibitor. For example, differentiation medium used to promote differentiation of pluripotent cells (e.g., differentiation into midbrain dopaminergic progenitor cells) may include a single BMP inhibitor (such as LDN-193189 or dorsomorphin; e.g., days 1-17 of differentiation); an activator of Sonic Hedgehog (SHH) signaling (such as purmorphamine, human C25II SHH, or mouse C24II SHH; e.g., days 1-6, 2-7, or 1-7); an activator of Wnt signaling (such as a GSK inhibitor, e.g., CHIR99021; e.g., days 2-17 or 3-17), and / or a MEK inhibitor (such as PD0325901; e.g., days 2-4 or 3-5). In some embodiments, a single TGF-β inhibitor (such as SB-431542; e.g., days 1-4) can be used in place of a single BMP inhibitor; however, in some embodiments, a single BMP inhibitor may increase FOXA2 expression in cells compared to the use of a single TGF-β inhibitor. + / LMX1A + In some embodiments, FGF-8 (e.g., FGF-8b) is not included in the differentiation medium on the first day or on days 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or any combination thereof (e.g., days 1-8); for example, in some embodiments, FGF-8 is included in the differentiation medium on days 9, 10, 11, 12, 13, 14, 15, 16, and 17, or any combination thereof. In various embodiments, the differentiation medium may include TGFβ and bFGF, or the differentiation medium may be essentially free of TGFβ and bFGF.

[0161] In certain aspects, the differentiation methods according to the embodiments include, for example, a method for differentiation of cells comprising: - in adherent cultures in medium containing a single BMP inhibitor (or TGFβ inhibitor); an activator of Sonic Hedgehog (SHH) signaling; and an activator of Wnt signaling; - in suspension (cell aggregates are formed) in a medium containing a single BMP inhibitor (or TGFβ inhibitor); an activator of SHH signaling; and an activator of Wnt signaling; - Passaging of cells through various media conditions cultured in adherent culture in neurobasal medium containing B27 supplement, L-glutamine, BDNF, GDNF, TGFβ, ascorbic acid, dibutyryl cAMP, and DAPT (and optionally lacking exogenously added retinol or retinoic acid) for maturation.

[0162] The basal medium may be any chemically defined medium, such as Basal Eagle Medium (BME), BGJb, CMRL 1066, Glasgow MEM, Improved MEM Zinc Option, Iscove's Modified Dulbecco's Medium (IMDM), Medium 199, Eagle MEM, αMEM, DMEM, Ham, RPMI 1640, and Fisher's medium, variants or combinations thereof, with or without TGFβ and bFGF.

[0163] In further embodiments, the cell differentiation environment may also include supplements, such as B-27 supplement, insulin, transferrin, and selenium (ITS) supplement, L-glutamine, NEAA (non-essential amino acids), P / S (penicillin / streptomycin), N2 supplement (5 μg / mL insulin, 100 μg / mL transferrin, 20 nM progesterone, 30 nM selenium, 100 μM putrescine (Bottenstein, and Sato, 1979 PNAS USA 76, 514-517), and / or β-mercaptoethanol (β-ME). It is contemplated that additional factors may or may not be added, including, but not limited to, fibronectin, laminin, heparin, heparin sulfate, retinoic acid.

[0164] Growth factors may or may not be added to the differentiation medium. In addition to or instead of the factors outlined above, growth factors such as members of the epidermal growth factor family (EGF), members of the fibroblast growth factor family (FGF) including FGF2 and / or FGF8, members of the platelet-derived growth factor family (PDGF), antagonists of the transforming growth factor (TGF) / bone morphogenetic protein (BMP) / growth and differentiation factor (GDF) family can be used at various steps of the process. In some embodiments, FGF-8 is included in the differentiation medium as described herein. Other factors that may or may not be added to the differentiation medium include molecules that can activate or inactivate signaling through the Notch receptor family, including, but not limited to, proteins of the delta-like and Jagged families, and other inhibitors of Notch processing or cleavage, such as gamma secretase inhibitors and DAPT. Other growth factors may include members of the insulin-like growth factor family (IGF), wingless-related (WNT) factor family, and hedgehog factor family.

[0165] Additional factors can be added to the aggregate formation and / or differentiation medium to promote proliferation and survival of neural stem / progenitor cells and survival and differentiation of neurons. These neurotrophic factors include, but are not limited to, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 / 5 (NT-4 / 5), interleukin-6 (IL-6), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), cardiotrophins, members of the transforming growth factor (TGF) / bone morphogenetic protein (BMP) / growth and differentiation factor (GDF) family, neurturin, neublastin / artemin, and persephin, members of the glial-derived neurotrophic factor (GDNF) family, and factors related to and including hepatocyte growth factor. Neuronal cultures that terminally differentiate to form postmitotic neurons may also contain a mitotic inhibitor or a mixture of mitotic inhibitors, including, but not limited to, 5-fluoro 2'-deoxyuridine, mitomycin C, and / or cytosine β-D-arabino-furanoside (Ara-C).

[0166] The medium may be a serum-containing medium or a serum-free medium. Serum-free medium may refer to a medium that does not contain raw or unpurified serum, and thus may include a medium containing purified blood-derived components or animal tissue-derived components (such as growth factors). In terms of preventing contamination with components derived from different animals, the serum may be derived from the same animal as the stem cells. In some embodiments, the medium is a defined medium, and the medium does not contain serum or other animal tissue-derived components (such as medium conditioned with irradiated mouse fibroblasts or irradiated fibroblast feeder cells).

[0167] The medium may or may not contain a serum replacement. The serum replacement may include materials that suitably contain albumin (such as lipid-rich albumin, albumin substitutes such as recombinant albumin, vegetable starch, dextran, and protein hydrolysates), transferrin (or other iron transporters), fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thiolglycerol, or equivalents thereof. For example, serum replacement may be prepared by the methods disclosed in WO 98 / 30679. Alternatively, commercially available materials may be used for greater convenience. Commercially available materials include knockout serum replacement (KSR) and chemically defined lipid concentrate (Gibco).

[0168] The medium may also contain fatty acids or lipids, amino acids (such as non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, pyruvic acid, buffers, and inorganic salts. The concentration of 2-mercaptoethanol may be, for example, about 0.05 to 1.0 mM, particularly about 0.1 to 0.5, or 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.2, 0.5, 0.8, 1, 1.5, 2, 2.5, 5, 7.5, 10 mM, or any intermediate value, but the concentration is not particularly limited thereto, as long as it is suitable for culturing stem cells.

[0169] In some embodiments, pluripotent stem cells are cultured in medium prior to aggregate formation (e.g., prior to dissociation into single cells or small aggregates to induce aggregate formation) to improve neural induction and floor plate patterning. In certain embodiments of the invention, stem cells may be cultured in the absence of feeder cells, feeder cell extracts, and / or serum.

[0170] E.Culture conditions The culture vessels used for culturing the cells may include, but are not limited to, flasks, tissue culture flasks, spinner flasks, dishes, Petri dishes, tissue culture dishes, multi-dishes, microplates, microwell plates, multi-plates, multi-well plates, microslides, chamber slides, tubes, trays, CELLSTACK® chambers, culture bags, and roller bottles, as long as the cells can be cultured. The cells may be cultured in a volume of at least or about 0.2, 0.5, 1, 2, 5, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 800, 1000, 1500 ml, or any range of volumes derivable therein, depending on the needs of the culture. In certain embodiments, the culture vessel may be a bioreactor, which may refer to any device or system that supports a biologically active environment. The bioreactor has a volume of at least or about 2, 4, 5, 6, 8, 10, 15, 20, 25, 50, 75, 100, 150, 200, 500 liters, 1, 2, 4, 6, 8, 10, 15 cubic meters, or any range derivable therein.

[0171] The culture vessel surface can be prepared with or without cell adhesives depending on the purpose. The cell-adhesive culture vessel can be coated with any substrate for cell adhesion, such as extracellular matrix (ECM), to improve the adhesion of the vessel surface to cells. The substrate used for cell adhesion can be any material intended to adhere stem cells or feeder cells (if used). Non-limiting substrates for cell adhesion include collagen, gelatin, poly-L-lysine, poly-D-lysine, poly-L-ornithine, laminin, vitronectin, and fibronectin, and mixtures thereof, such as protein mixtures from Engelbreth-Holm-Swarm mouse sarcoma cells (such as Matrigel™ or Geltrex) and lysed cell membrane preparations (Klimanskaya et al., 2005). In some embodiments, the cell-adhesive culture vessel is coated with a cadherin protein, such as epithelial cadherin (E-cadherin).

[0172] Other culture conditions can be appropriately determined. For example, the culture temperature can be about 30 to 40°C, for example, but not limited to, at least or about 31, 32, 33, 34, 35, 36, 37, 38, 39°C. The CO2 concentration can be about 1 to 10%, for example, about 2 to 7%, or any range that can be derived therein. The oxygen pressure can be at least or about 1, 5, 8, 10, 20%, or any range that can be derived therein.

[0173] Adherent cultures can be used in certain aspects. Optionally, cells can be cultured in the presence of feeder cells. When feeder cells are used, stromal cells such as fetal fibroblasts can be used as feeder cells (see, for example, Manipulating the Mouse Embryo A Laboratory Manual (1994); Gene Targeting, A Practical Approach (1993); Martin (1981); Evans et al. (1981); Jainchill et al., (1969); Nakano et al., (1996); Kodama et al. (1982); and WO 01 / 088100 and US 2005 / 080554). In some embodiments, feeder cells are not included in the cell culture medium and cells can be cultured using defined conditions.

[0174] In other embodiments, suspension cultures can be used. Suspension cultures that can be used include suspension cultures on carriers (Fernandes et al., 2007) or gel / biopolymer encapsulation (US Patent Publication No. 2007 / 0116680). Suspension cultures of stem cells generally involve the culture of cells (e.g., stem cells) under non-adherent conditions with respect to the culture vessel or feeder cells (if used) in the medium. Suspension cultures of stem cells generally include isolated cultures of stem cells and aggregate suspension cultures of stem cells. Isolated cultures of stem cells include the culture of suspended stem cells, such as a single stem cell or small cell aggregates of stem cells consisting of multiple stem cells (e.g., about 2-400 cells). Continuing the isolated culture usually results in the culture of isolated cells forming larger aggregates of stem cells, which can then be used to generate or utilize aggregate suspension cultures. Aggregation suspension culture methods include the embryoid culture method (see Keller et al., 1995) and the SFEB (serum-free embryoid body) method (Watanabe et al., 2005; WO 2005 / 123902).

[0175] In certain aspects, non-static cultures can be used for the culture and differentiation of pluripotent stem cells. Non-static cultures can be any culture where cells are kept at a controlled moving speed, for example, by using a shaking, rotating, or agitation platform, or culture vessel, especially a large volume rotating bioreactor. In some embodiments, a rocker table can be used. Agitation improves the circulation of nutrients and cell waste products, and agitation can also be used to control cell aggregation by providing a more uniform environment. For example, the rotation speed can be set to at least or up to about 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100 rpm, or any range derivable therein. The incubation period in non-static cultures of pluripotent stem cells, cell aggregates, differentiated stem cells, or progeny cells derived therefrom can be at least or about 4 hours, 8 hours, 16 hours, or 1, 2, 3, 4, 5, 6 days, or 1, 2, 3, 4, 5, 6, 7 weeks, or any range derivable therein.

[0176] In some embodiments of pluripotent stem cell culture, when the culture vessel is full, the colonies are split into aggregated or even single cells by any method suitable for separation, and these cells are then placed into a new culture vessel for passaging. Cell passaging or splitting is a technique that allows cells to survive and grow under culture conditions for an extended period of time. Cells will typically be passaged when they are about 70%-100% confluent.

[0177] Single cell isolation of pluripotent stem cells followed by single cell passaging can be used in the present methods with several advantages, such as facilitating defined seeding for cell growth, cell sorting, and differentiation, and allowing automation of culture procedures and clonal expansion. For example, progeny cells obtained by cloning from single cells may be homogenous in genetic makeup and / or synchronized in cell cycle, which may facilitate targeted differentiation. Exemplary methods of single cell passaging may be described in US Patent Publication No. 2008 / 0171385, which is incorporated herein by reference.

[0178] F. Cryopreservation The cells produced by the methods disclosed herein can be cryopreserved at any stage of the process, such as stage I, stage II, or stage III, see, for example, PCT Publication WO 2012 / 149484 A2, which is incorporated herein by reference. The cells can be cryopreserved with or without a substrate. In some embodiments, the storage temperature is in the range of about -50°C to about -60°C, about -60°C to about -70°C, about -70°C to about -80°C, about -80°C to about -90°C, about -90°C to about -100°C, and overlapping ranges thereof. In some embodiments, lower temperatures are used for storage (e.g., maintenance) of the cryopreserved cells. In some embodiments, liquid nitrogen (or other similar liquid coolant) is used to preserve the cells. In further embodiments, the cells are preserved for more than about 6 hours. In further embodiments, the cells are preserved for about 72 hours. In some embodiments, the cells are preserved for 48 hours to about 1 week. In yet other embodiments, the cells are stored for about 1, 2, 3, 4, 5, 6, 7, or 8 weeks. In further embodiments, the cells are stored for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. The cells can also be stored for longer periods of time. The cells can be cryopreserved separately or on a substrate, such as any of the substrates disclosed herein.

[0179] In some embodiments, an additional cryoprotectant can be used. For example, cells can be cryopreserved in a cryopreservation solution that includes one or more cryoprotectants, such as DM80, and serum albumin, such as human or bovine serum albumin. In certain embodiments, the solution includes about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% DMSO. In other embodiments, the solution includes about 1% to about 3%, about 2% to about 4%, about 3% to about 5%, about 4% to about 6%, about 5% to about 7%, about 6% to about 8%, about 7% to about 9%, or about 8% to about 10% dimethyl sulfoxide (DMSO) or albumin. In certain embodiments, the solution includes 2.5% DMSO. In another specific embodiment, the solution includes 10% DMSO.

[0180] The cells may be cooled, for example, at about 1° C. / min during cryopreservation. In some embodiments, the cryopreservation temperature is about −80° C. to about −180° C. or about −125° C. to about −140° C. In some embodiments, the cells are cooled to 4° C. before cooling at about 1° C. / min. The cryopreserved cells may be transferred to the vapor phase of liquid nitrogen before thawing for use. In some embodiments, for example, once the cells reach about −80° C., they are transferred to a liquid nitrogen storage area. Cryopreservation may also be performed using a controlled rate freezer. The cryopreserved cells may be thawed, for example, at a temperature of about 25° C. to about 40° C., typically at a temperature of about 37° C.

[0181] III.How to use The present disclosure provides methods for generating iPSC-derived dopaminergic neurons with disease-associated mutations. These can be used for several important research, development, and commercial purposes, including but not limited to in vivo cell transplantation or implantation; in vitro screening of cytotoxic compounds, carcinogens, mutagens, growth / regulatory factors, pharmaceutical compounds, etc.; studying the mechanisms by which drugs and / or growth factors act; diagnosing and monitoring cancer in patients; gene therapy; and producing biologically active products, to name just a few.

[0182] The midbrain DA progenitor cells provided herein (e.g., D17 cells) can be used to screen factors (such as solvents, small molecule drugs, peptides, and polynucleotides) or environmental conditions (such as culture conditions or manipulations) that affect the properties of the DA neurons provided herein.

[0183] In some applications, stem cells (differentiated or undifferentiated) are used to screen for factors that promote maturation of cells along neural lineages, or factors that promote the proliferation and maintenance of such cells in long-term culture. For example, candidate neural maturation or growth factors can be tested by adding them to stem cells in different wells and then determining any resulting phenotypic changes according to the desired criteria for further culture and use of the cells.

[0184] The cell cultures provided herein can be used, for example, to test the effect of molecules on neuronal differentiation or survival, or for toxicity testing, or for testing the effect of molecules on neuronal or neuronal function. This can include screening to identify compounds that affect neuronal activity, plasticity (e.g., long-term potentiation), or function. The cell cultures can be used to discover, develop, and test new drugs and compounds that interact with and affect the biology of neural stem cells, neural progenitor cells, or differentiated neural cells or neuronal cell types. Neuronal cells are also highly useful in studies designed to identify the cellular and molecular basis of neural development and dysfunction, including, but not limited to, axon guidance, neurodegenerative diseases, neuroplasticity, and learning and memory. Such neurobiology studies can be used to identify novel molecular components of these processes, provide new uses for existing drugs and compounds, and identify new drug targets or drug candidates.

[0185] In some applications, compounds can be screened or tested for their potential neurotoxicity. Cytotoxicity can be determined first by the effect on cell viability, survival, morphology, or enzyme leakage into the medium. In some embodiments, tests are performed to determine whether a compound affects cell function (such as neurotransmission or electrophysiology) without causing toxicity.

[0186] In some embodiments, one or more specific compounds may be tested to determine whether the compound has an effect that may be beneficial in treating the disease. Based on the effect of the compound on functional activity, it may be possible to determine whether the compound may be useful in treating the disease. In some embodiments, the cells are derived from iPS cells from a subject with a disease (e.g., a genetic disease or a disease with a genetic component or risk factor), such as a neurological or neurodegenerative disease (e.g., autism, epilepsy, ADHD, schizophrenia, bipolar disorder, etc.). In some embodiments, the cells may be cultured in the presence of a first compound or toxin, such that the neuronal culture exhibits similar characteristics to the disease state. In these embodiments, a second compound may be provided to the cell culture to determine whether the second compound can alleviate or reduce the effects of the first compound or toxin. In other embodiments, the cell culture may be used to determine whether the compound produces a toxic or adverse effect on the cell culture.

[0187] For example, one or more candidate drugs can be added to the culture medium at various concentrations. Drugs that promote the expression of the polypeptide of interest expressed in the cells are considered to be useful. Such drugs can be used as therapeutic agents to prevent, delay, ameliorate, stabilize, or treat injuries, diseases, or disorders characterized by defects in neurodevelopment or neurofunction. The identified drugs can be used to treat or prevent neurological conditions. In another embodiment, the activity or function of cells of the organoid is compared in the presence and absence of the candidate compound. Compounds that desirably change the activity or function of cells are selected as useful in the method.

[0188] Agents useful in the present method can be identified from large libraries of natural products or synthetic (or semi-synthetic) extracts, or chemical libraries, or polypeptide or nucleic acid libraries, according to methods known in the art. Those skilled in the art of drug discovery and development will understand that the exact source of the test extract or compound is not critical to the screening procedure of the method of the present invention. Agents used for screening can include known agents known as therapeutic agents for the treatment of neurological conditions. Alternatively, virtually any number of unknown chemical extracts or compounds can be screened using the methods described herein. Examples of such extracts or compounds include, but are not limited to, plant, fungal, prokaryotic or animal-based extracts, fermentation broths, and synthetic compounds, as well as modifications of existing polypeptides.

[0189] Assays for determining the functional activity of cells may include viability assays, GBA assays, calcium assays, MEA assays, synaptic pruning by microscopy assays, signal transduction tracking phosphorylated intermediates of various pathways, analysis of analytes released into the culture medium including normal and disease-specific cell types. For example, for disease modeling applications comparing isogenically engineered or patient-specific cells to AHN controls, treatment or exposure to neurogenerative proteins such as amyloid beta, myelin, synaptosomes, or tau will decrease calcium signaling and electrical activity and increase neuroinflammatory cytokines. For example, an increase in any of these functional activity measures (e.g., greater than 30%, 40%, 50%, 60%, 70%, 80%, or 90%) may indicate a candidate drug.

[0190] In some embodiments, early pathogenic changes can be quantified by observing changes or primarily downregulation of gene expression profiles associated with the onset of neurodegeneration, in certain embodiments, upregulation of immune-related genes associated with the release of neuroinflammatory cytokines can be measured as associated with neurodegeneration.

[0191] The assay may be performed in a high-throughput manner. For example, cell cultures can be placed or placed on culture dishes, flasks, roller bottles or plates (e.g., single multi-well dishes or dishes such as 8, 16, 32, 64, 96, 384 and 1536 multi-well plates or dishes), optionally in defined locations, for the identification of potential therapeutic molecules. Screenable libraries include, for example, small molecule libraries, siRNA libraries, adenovirus transfection vector libraries. The screening platform can be automated, such as robotic automation. The culture platform can include an automated cell washer and a high content imager.

[0192] In some embodiments, the assay can quantify the response of the cell cultures to different neuroinflammatory stimuli that mimic sterile bacterial infection (lipopolysaccharide (LPS) exposure), mechanical injury (scratch wound), and seizure activity (glutamate-induced excitotoxicity). The secreted cytokine profiles of control and LPS-exposed cultures can be measured.

[0193] The models described herein can be used for compound or treatment screening or testing (e.g., for efficacy, toxicity, or other metabolic or physiological activity), such as for pharmacodynamic or pharmacokinetic testing of drug crossing the blood-brain barrier. Such testing can be performed by providing the models described herein under conditions that maintain the constituent cells of the product in a viable state (e.g., in an oxygenated medium); applying the compound to be tested (e.g., a drug candidate) to the cells (e.g., by administration to the endothelial layer); and then detecting the penetration of the compound through the endothelial layer and / or other physiological responses (e.g., injury, scar tissue formation, infection, cell proliferation, bum, cell death, release of markers such as histamine release, cytokine release, genetic changes, etc.), which can indicate whether the compound can cross the blood-brain barrier and / or has a therapeutic effect, toxicity, or other metabolic or physiological activity in the brain when delivered systemically (e.g., intravascularly) to a mammalian subject. A control sample of the model may be maintained under similar conditions and a control compound (e.g., saline, complex vehicle or carrier) applied thereto to obtain comparative results, or damage may be determined based on comparison with historical data or data obtained by application of dilutions of test compounds, etc.

[0194] Methods for determining whether a test compound has immune activity can include testing immunoglobulin production, chemokine production, and cytokine production by DA neurons in a cell model.

[0195] Methods of crossing the blood-brain barrier (e.g., the human blood-brain barrier) that can be tested using the models taught herein include, but are not limited to, differential paracellular tight junction permeability, passive diffusion through cell layers, receptor-mediated transcytosis, and / or cellular efflux inhibition.

[0196] In some embodiments, the model may be used for subject-specific testing (e.g., for efficacy, toxicity, or other metabolic or physiological activity), where at least some of the cells in the model are from the subject, such as for pharmacodynamic or pharmacokinetic testing of blood-brain barrier passage of drugs. For example, fibroblasts from a subject may be directed into induced pluripotent stem cells (e.g., induced pluripotent neural stem cells), which may then be directed into one or more cell types for the model, such as neurons, oligodendrocytes, endothelial cells, astrocytes, or microglia.

[0197] The terms "neurodegenerative disease or disorder" and "neurological disorder" include diseases or disorders that primarily involve the peripheral or central nervous system. The compounds, compositions, and methods provided herein can be used to treat neurological or neurodegenerative diseases and disorders. As used herein, the terms "neurodegenerative disease", "neurodegenerative disorder", "neurological disease", and "neurological disorder" are used interchangeably.

[0198] Examples of neurological disorders or diseases include diabetic peripheral neuropathy (including third nerve palsy, mononeuropathy, multiple mononeuropathy, diabetic amyotrophy, autonomic neuropathy, and thoracic and abdominal neuropathy), Alzheimer's disease, age-related memory decline, senility, age-related dementia, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multiple system degeneration (Shy-Drager syndrome), motor neuron diseases including amyotrophic lateral sclerosis ("ALS"), degenerative ataxias, corticobasal degeneration, Guam ALS-Parkinson's disease-dementia complex, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, multiple sclerosis ("MS"), synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado-Jackson syndrome ... These include, but are not limited to, chronic neurological disorders such as Joseph's disease / Spinocerebellar ataxia type 3 and olivopontocerebellar degeneration, Gilles de la Tourette's disease, bulbar and pseudobulbar palsy, spinal and spinal muscular atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic paraplegia, Wernicke-Korsakoff related dementia (alcohol-induced dementia), Werdnig-Hoffmann disease, Kugelberg-Welander disease, Tay-Sachs disease, Sandhoff disease, familial spastic disorders, Wohifart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, and prion diseases (including Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker disease, kuru, and fatal familial insomnia). Other conditions further included in the method of the present disclosure include age-related dementia and other dementias, as well as conditions involving memory loss, including vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia due to head trauma and diffuse brain injury, dementia pugilistica, and frontal lobe dementia. Also included are cerebral ischemia or infarction, including embolic and thrombotic occlusion, and other neurodegenerative diseases resulting from any type of intracranial hemorrhage (including but not limited to epidural, subdural, subarachnoid, and intracerebral), and intracranial and intravertebral lesions (including but not limited to contusion, penetration, shear, compression, and laceration). Thus, the term also encompasses acute neurodegenerative disorders, such as stroke, traumatic brain injury, schizophrenia, peripheral nerve injury, hypoglycemia, spinal cord injury, epilepsy, and those involving anoxia and hypoxia.

[0199] A. Pharmaceutical Compositions Also provided herein are pharmaceutical compositions and formulations comprising the cells and a pharma- ceutically acceptable carrier.

[0200] Thus, the cell composition for administration to a subject according to the present invention can be formulated in any conventional manner using one or more physiologically acceptable carriers, including excipients and auxiliaries that facilitate processing of the compound into a medicament that can be used. The appropriate formulation will vary depending on the selected route of administration.

[0201] The pharmaceutical compositions and formulations described herein comprise an active ingredient (such as cells) having a desired degree of purity in the form of a lyophilized formulation or an aqueous solution, optionally in one or more pharma- ceutical acceptable carriers (see Remington's Pharmaceutical Sciences 22). ndPharmaceutically acceptable carriers are generally non-toxic to recipients at the dosages and concentrations employed and include buffers such as phosphate, citric acid, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; Examples of suitable pharmacopoeitic carriers include, but are not limited to, proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmacopoeitic carriers herein further include interstitial drug dispersion agents such as soluble neutral active hyaluronidase glycoproteins (sHASEGPs), e.g., human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Application Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one embodiment, a sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.

[0202] A. Distribution for Commercial, Therapeutic and Research Purposes In some embodiments, a reagent system is provided that includes cells present at any time during manufacture, distribution, or use. Kits may include any combination of cells described in this disclosure in combination with undifferentiated pluripotent stem cells or other differentiated cell types, often sharing the same genome. Each cell type may be packaged together, in separate containers in the same facility, or at different locations at the same or different times, under the control of the same or different entities that share a business relationship. Pharmaceutical compositions may be packaged in appropriate containers, optionally with written instructions for the desired purpose, such as mechanistic toxicity.

[0203] In some embodiments, kits are provided that may include, for example, one or more media and components for producing cells. The reagent system may be packaged in either aqueous media or lyophilized form, as appropriate. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe, or other container means into which the components may be placed and preferably appropriately divided. If the kit includes multiple components, the kit will generally also include a second, third, or other additional container into which the additional components may be separately placed. However, various combinations of components may be included in the vials. The components of the kits may be provided as dry powders. If the reagents and / or components are provided as dry powders, the powders can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means. The kits of the present disclosure will also typically include a means for containing the components of the kit in close confinement for commercial sale. Such containers may include injection or blow molded plastic containers into which the desired vials are retained. The kits may also include instructions for use, such as in electronic, such as printed or digital, format. EXAMPLES

[0204] IV. Working Examples The following examples are included to demonstrate preferred embodiments of the invention. Those skilled in the art should understand that the techniques disclosed in the following examples represent techniques discovered by the inventors to work well in the practice of the invention, and therefore can be considered to constitute preferred modes for its practice. However, those skilled in the art should understand in light of this disclosure that many modifications can be made to the specific embodiments disclosed and still obtain the same or similar results without departing from the spirit and scope of the invention.

[0205] Example 1 - Generation and characterization of iPSC-derived DA neurons Episomal reprogrammed iPSC 01279 was engineered to generate heterozygous (HZ) SNCA A53T mutant (Figure 1A). SNCA A53T HZ (SNCA A53T) iPSC was engineered from AHN iPSC 01279 by nuclease-mediated homologous recombination and donor oligo SJD 14-132 (SEQ ID NO: 1: GTTTTACAATTTCATAGGAATCTTGAATACTGGGCCACACTAATCACTAGATACTTTAAATATCATCTTTGGATATAAGCACAATGGAGCTTACCTGTgGtgACACCATGCACCACTCCCTCCTTGGTTTTGGAGCCTACAAAAACAAATTCAAGACATAAGTCTCAAGCTAGCCTTAAATTGCTGATTAGCTAGTTTTC). The resulting iPSCs contained the SNP rs104893877, which changed amino acid 53 from alanine to threonine, resulting in the A53T variant, resulting in the SNCA A53T heterozygous iPSC line (SNCA A53T), which carries the disease α-synuclein gene (SNCA) and two silent mutations in PD. This procedure is shown diagrammatically in Figure 1B, with the alanine to threonine change at amino acid 53 highlighted in yellow.

[0206] Next, iPSCs were obtained from a PD patient carrying a GBA N370S mutation. The amino acid change of asparagine 370 to serine is highlighted in yellow in Figure 1B. iPSCs were derived from a PD patient carrying an LRRK2 G2019S mutation, shown diagrammatically, and showing the amino acid change of glycine 2019 to serine, highlighted in yellow in Figure 1C. Cytogenetic analysis of G-banded metaphase cells from each iPS cell line was performed to detail normal karyotype, SNCA A53T, GBA(N370S), and LRRK2(G2019S) (Figure 1D-1F). G-banded karyotyping was performed and analyzed by WiCell (Madison, WI).

[0207] A schematic diagram of the chronological differentiation process of iPSCs into dopaminergic neurons and the cytokines utilized throughout the process is shown in Figure 2A. Undifferentiated iPSCs were cultured feeder-free on MATRIGEL®-coated plates and maintained using E8 medium (Thermo Fisher). Neuronal patterning was initiated on D0 by replacing the E8 medium and adding DMEM / F12 basal medium [containing N2 (1X), B27(-vitA) (1X) neuronal supplement (Gibco), LDN193189, SB431542, SHH, purmorphamine, and CHIR99021]. On day 5, cells were dissociated and cultured in spinner flasks as aggregates. The cells were cultured in DMEM / F12 basal medium [containing N2 (1X), B27(-vitA) (1X), neuronal supplement (Gibco), LDN193189, CHIR99021, and FGF8] for 12 days. The cells were harvested on day 17 and assessed by flow cytometry by staining for FOXA2 and LMX1. The cells were further matured in neuronal maturation medium (Neurobasal medium + neuronal supplement and neuronal supplement B (FCDI) and DAPT (Tocris)) for 20 days and dissociated and cryopreserved on day 37. Representative flow cytometry dot plots of dopaminergic progenitor cells at day 17 expressing midbrain transcription factors FOXA2 and LMX1 are shown in Figure 2B. Figure 2C shows representative flow cytometry dot plots of dopaminergic neurons at the end of the process expressing the enzyme tyrosine hydroxylase (TH) and FOXA2, an enzyme required for dopamine synthesis from tyrosine.

[0208] [Table 1]

[0209] Immunofluorescence staining was performed on terminal DA neurons (Figures 3A-3B). Cryopreserved DA neurons were thawed and plated in a 96-well Greiner imaging plate at 200K / cm. 2Cells were plated on iPSCs at 3 and 14 days post-thawing with 4% paraformaldehyde in PBS for 20 min. Cells were fixed with 4% paraformaldehyde in PBS for 20 min on days 3 and 14 post-thawing. The cells were stained with fluorescein-labeled secondary antibodies for 1 h at room temperature, counterstained with Hoechst for 20 min, and washed. Samples were imaged with ImageXpress (Molecular Devices) (Figure 3B). Flow cytometry analysis was performed for quantification of FOXA2 and TH protein in dopaminergic neurons (Figure 3C). Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were plated and harvested with Accutase for 15 min at 37°C on days 3 and 14. Cells were stained with LIVE / DEAD™ Fixable Red Dead Cell Stain Kit (ThermoFisher) and then fixed with 4% paraformaldehyde in PBS for 20 min. The cells were stained for the presence of FOXA2 and TH expression and quantified by intracellular flow cytometry.

[0210] DA neurons derived from GBA and LRRK2 patient iPSCs showed abnormal mRNA and protein expression of enzymes involved in the synthesis and degradation of dopamine (Figure 4A). TH, DDC, MAOA, and COMT transcript levels were quantified in DA neurons derived from ANH, engineered, and PD patients. Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were plated, harvested 14 days after thawing, and pellets were submitted for RNA-Seq analysis. Quantification of TH, DDC, MAOA, and COMT transcripts across multiple lots of DA neurons using (FPKM) values ​​was analyzed (Figure 4B). TH and DDC protein levels were quantified in DA neurons derived from ANH, engineered, and PD patients. Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were plated and harvested 14 days after thawing, and cell lysates were loaded onto capillaries probed with TH (1:250, T2928 Sigma), GBA (1:100, R&D MAB4710), DDC (1:500, Novus Biologicals NB300-174), MAPT (1:1000, MAB361 Millipore), and the presence of TH and GBA protein was detected using the Protein Simple system according to the manufacturer's instructions. TH and DDC protein were quantified based on the area under the curve for each protein and normalized to MAPT expression. ( * P value < 0.05, ** P value < 0.01, *** P value < 0.001) (Figure 4C).

[0211] DA neurons derived from GBA and LRRK2 PD patient iPSCs released more dopamine when stimulated with KCl (Figure 5A). Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and cultured for 21 days, and the levels of dopamine released from the cells were quantified using a competitive dopamine ELISA according to the manufacturer's instructions (Eagle Biosciences Cat. No. DOP31-K01). Three technical replicates were performed for each biological sample. Standard curves were graphed in Graphpad PRISM and shown in Figure 5A. Quantification of dopamine was performed using nonlinear regression using a log (agonist) vs. response-variable slope (four parameters) model. Dopamine release of DA neurons was compared to dopamine released by AHN DA neurons when stimulated with KCL on day 21 of culture in HBSS buffer (Figure 5B) ( * P value < 0.05, ** P value < 0.01, *** P value < 0.001).

[0212] DA neurons derived from SNCA-manipulated iPSCs and PD patient iPSCs revealed higher cell death and mitochondrial stress (Figure 6A). Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated. Temporal viability and mitochondrial oxidative stress of DA neurons were quantified by live culture staining with calcein AM and YOYO-3 to quantify live and dead cells at different time points over a 38-day culture. Representative staining of terminal DA neurons 21 days after thawing with 1 μM YOYO-3 iodide and calcein AM is shown in Figure 6A. Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated at a density of 64,000 cells per well in 96-well optical plates. Cells were incubated with 1 μM YOYO-3 iodide and 1 μM calcein AM (Thermo Fisher) for 30 min at room temperature and imaged every 30 min for 3 h on an Incucyte S3 (Figure 6B). The percentage of live / dead cells was calculated based on positive objects in the green and red channels. Cells were washed with PBS, lysed in CellTiter-Glo Cell Viability Assay Buffer, shaken for 1 min, and then incubated for 10 min. Luminescence signals were captured and quantified using a CLARIOstar plate reader (Molecular Devices). Data were collected from one well (0.143 cm) of a 96-well plate. 2 ) are shown. Figure 6C shows a representative image of a DA neuron stained with MitoSOX dye (left image) overlaid with a phase image (middle image) and a DA neuron co-stained with Calcein AM for live cells (right image).

[0213] Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated. MitoSOX red (5 μM) was added to neurons and incubated at 37 °C for 30 min. MitoSOX was then removed and calcein AM (Thermo Fisher, C1430) was added to neurons and imaged every 30 min for 3 h in an Incucyte S3. Rotenone (a mitochondrial toxin) at 2 μM was used as a positive control. Positive control neurons were treated with rotenone for 30 min at 37 °C followed by washing with complete neuronal medium. Quantification of MitoSOX signal intensity (mean ± SD) and percentage of MitoSOX positive cells in diseased neurons compared to AHN neurons was determined and the results were compared to ROS in mitochondria induced by rotenone (Figures 6D-6E).

[0214] SNCA-engineered iPSCs and DA neurons from PD patients had significantly more aSyn protein aggregates (Figure 7). α-synuclein protein aggregates were observed in DA neurons. Thioflavin (Th-T) staining was performed to reveal aggregated aSyn on live DA neuron cultures at 22 DIV after addition of oligomeric aSyn (4 μM / ml) for 24 h (Figure 7A). All aSyn +Cells were counted and plotted against Th-T signal intensity of individual neurons in different expression bins (Figure 7B). Th-T images were quantified on day 21 of culture treated with active oligomer aSyn for 24, 48, or 72 hours (n=4, one-way ANOVA with Dunnett's multiple comparison test) (Figure 7C). For α-synuclein protein aggregation assay (Th-T staining), cells were seeded at a density of 64K per well in 96-well plates for Th-T staining. On day 21, post-thawing cells were treated with 4ug / ml recombinant mouse α-synuclein protein aggregates (Active) (Abcam, ab246002) for 24, 48, and 72 hours and then stained with Thioflavin T. Thioflavin T (Th-T) (Abcam, ab120751) was dissolved in HBSS (Th-T was completely dissolved at a concentration of 8mg / ml (2mM) at 37℃). Cells were stained with Th-T dye (final concentration 10 μM) and iodide YOYO-3 (Thermofisher-Y3606 1 uM) in culture medium. Cells were incubated for 30 min, washed with warm HBSS, and imaged with an Incucyte 20x objective. The intensity of Th-T signal was quantified in each neuron under various conditions using Incucyte software.

[0215] DA neurons derived from SNCA engineered iPSCs and PD patient iPSCs had greater aSyn aggregation (Figure 8). Quantification of α-synuclein protein aggregation was performed using the Meso Scale Diagnostics (MSD) U-PLEX Human α-synuclein kit (MSD-K15). Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated for 21 days (Figure 8B) or 42 days (Figure 8C) in culture. Cells were lysed in RIPA lysis buffer (Cell Signaling) supplemented with Halt protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific), and protein content was measured using the Pierce BCA protein assay (Thermo Fisher Scientific). Quantification of human α-synuclein was performed using the MSD-K15 kit from MSD. Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and cultured for up to 42 days. Analyte concentrations were determined from the ECL signal by backfitting to standard curves (Figure 8A). Calculations to establish standard curves and determine concentrations were performed using MSD DISCOVERY WORKBENCH® analysis software. α-synuclein protein concentration in AHN was 34 ng / ml ± 0.16, whereas SNCA = 66.5 ng / ml ± 2.44, GBA = 89.5 ng / ml ± 4.45, and LRRK2 = 53 ng / ml ± 0.68 (mean ± SD). Anytime α-synuclein protein concentration in more than 20% of AHN cells can be considered pathological.

[0216] DA neurons derived from SNCA-manipulated iPSCs and PD patient iPSCs were observed to have low GCase activity. Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated for 14 days, and samples were harvested and submitted for RNASeq and Western blot analysis. FPKM values ​​of GBA transcripts were quantified (Figure 9A). Total cell lysates from all samples containing 2.5 μg protein were loaded into gel capillaries using a Protein Simple device to confirm detection of 66 kd GBA protein. The amount of GBA protein in the lysates was quantified based on the area under the curve for each protein and normalized to MAPT expression (Figure 9B). Different concentrations of 4-methylumbelliferyl-β-D-glucopyranoside (4-MU) as substrate (Figure 9C) and the GCase-specific inhibitor conduritol B epoxide (CBE) (Figure 9D) were tested. 10 mM 4-MU and 2 mM CBE were found to be optimal concentrations and were used in the following GCase activity assay. Different concentrations of protein lysate were also tested for GCase activity from AHN DA neurons (Figure 9E). 5 μg of protein lysate was used to compare GCase activity between different DA neurons (Figure 9F). (n=4, p<0.001 one-way ANOVA with Dunnett's test for mean comparison). * P value < 0.05, ** P value < 0.01, *** P value < 0.001).

[0217] For GCase activity assays, multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated for 14 days. Cells were harvested, lysed, and centrifuged at 20,000×g for 20 min at 4°C. Total protein concentration was measured using the Pierce BCA protein assay (Thermo Fisher Scientific). 5 μg of protein per lysate was used to determine GCase activity in the presence of 1% BSA with 10 mM 4-methylumbelliferyl β-glucophyranoside (4-MU, Sigma-Aldrich, #M3633) (Figure 9C) and with or without 2 mM conduritol-b-epoxide (CBE) (Figure 9D). Recombinant human glucosylceramidase / GBA (rhGBA) (R&D, 7410-GHB-020) was used as a positive control. Samples were incubated at 37°C for 40 min and the reaction was stopped by adding an equal volume of 1 M glycine (pH 12.5). 100 μl of the reaction was loaded into a white 96-well plate (Nunc, #136101) and the fluorescence (ex=355 nm, em=460, 0.1 s) signal was measured in a CLARIOstar plate reader (Molecular Devices). Relative fluorescence units (RFU) of non-CBE treated lysates were calculated by subtracting the signal from the corresponding CBE treated lysates. AHN cells had higher GCase activity compared to the mutants (mean ± SD, AHN=31117±639, GBA=13622±385, LRRK2=20619±179, and SNCA=173429±29300).

[0218] DA neurons derived from SNCA-manipulated iPSCs and PD patient iPSCs revealed differences in the evolution of neural network activity (Figure 10). Multiple lots of cryopreserved DA neurons derived from GBA, LRRK2, SNCA, and AHN iPSCs were thawed and plated in 48-well Classic multielectrode array (MEA) plates (8 wells per lot at a cell density of 120K cells per well) in complete BrainPhys medium. Neuronal activity was quantified using Axion Maestro MEAs. MEAs were recorded every few days to monitor the development of synchronously bursting neuronal networks over time in culture. .RAW data files were converted to .spk files and subsequently analyzed using Axion's Neural Metric Tool software. Burst detection was performed using the "envelope method". Spontaneous action potentials (black ticks are "spikes") and burst behavior (blue ticks) were observed. Synchronous network bursts were also detected (see histogram peaks and corresponding pink / magenta boxes around clustered spikes below the bursts for all electrodes). As a result, quantification of burst rate, network burst frequency, and synchronization index over time (Figure 10B) revealed lower activity and network strength in GBA, LRRK2, and SNCA neurons compared to AHN cells in the raster plots at day 35 (Figure 10A).

[0219] For RNA-Seq analysis, dopaminergic neurons were thawed and maintained according to the iCell Dopa Neuron User's Guide. Briefly, 2.0E+6 cells were plated on PLO / laminin-coated 6-well tissue culture plates and cultured for >15 days after thawing. Cells were lysed directly in the wells using 400 microliters of Qiagen RLT+ lysis buffer. Duplicate samples / lots of approximately 2 million cells each were lysed and stored at -80°C until RNA extraction was performed. RNA was extracted using a QiaSymphony. To ensure acceptable sample purity, RNA concentrations should be >20ng / μL and the optical density ratio (OD 260 / 280) should be >2.0.

[0220] cDNA library preparation was performed at Novogene, and samples were tailed, ligated with modified oligos, size selected, and amplified. All libraries were then inspected prior to sequencing using (1) an Agilent BioAnalyzer for library sizing and quality assessment, and (2) qPCR to measure library concentration and the presence of Illumina anchor sequences. RNA sequencing was then performed using paired-end technology with a read length of 150 base pairs on an Illumina NovaSeq 6000 platform. Output data files, called "fastq" files, consisting of more than 20 million read pairs per sample, were then sent to FCDI on a hard drive. These raw data files were copied to a Linux cluster and archived after checking the file integrity. In silico sample QC to check for possible sample swapping was performed by aligning the reads to an in-house sequence database composed of human DNA and mRNA, mouse, phiX, viral, fungal, and bacterial sequences using an alignment program called bowtie2. Samples were considered to pass if they contained more than 75% human sequences. A quality report of the sequencing reads was generated using the FASTQC program. All high-quality reads were then aligned to the HG38 transcriptome using the splice-aware alignment program HISAT2. The alignment files (called bam files) were then used to create a read count matrix using the Rsubread::FeatureCounts program, which could be further used to perform differential expression analysis between samples of interest using the DESeq2 program. The normalized read counts were converted to log10(FPKM+0.0001) values, and simple scatter plots could be visualized with TIBCO Spotfire software.

[0221] Transcripts of mutant DA neurons were plotted against AHN DA neurons, showing high correlation in gene expression levels and highlighting significantly different transcripts (Figure 11A). Differential gene expression analysis of mutant samples compared to AHN samples was performed and the number of significantly changed transcripts was summarized in a Venn diagram (Figure 11B). Gene set enrichment and pathway analysis of differentially regulated transcripts in mutant DA neurons compared to AHN DA neurons in the DAVID database is shown in Figure 11C.

[0222] Compound screening selected 12 compounds that were previously shown to have a positive effect on improving GCase activity. DA neurons were cultured at high density (200,000 / well) in 96-well plates. Gcase activity was measured from GBA, LRRK2, and AHN iPSC-derived DA neurons after compound treatment. On day 18, cells were treated with different compounds at three concentrations (1x, 10x, and 100x of the compounds in Table 2) after thawing. 21 days after plating (3 days after treatment), cells were lysed using 100 μl of assay buffer and Gcase activity was measured using 5 μg of protein lysate. Net Gcase activity was graphed relative to 0.1% DMSO-treated cells as a negative control. Total protein in the lysates was quantified using the Pierce BCA Protein Assay Kit (ThermoFisher).

[0223] GCase activity can be used as a readout for compound screening of diseased neurons, where AHN serves as a control and compounds that can rescue GCase activity will be considered as positive hits. The effect of 12 compounds at three concentrations on Gcase activity in GBA and LRRK2 DA neurons with AHN as a control is shown in Figure 12A. In the combination screen, four molecules from the first screen that showed improved GCase activity were picked up and combined in different ways to test with GBA cells (Figure 12B). Single compounds were tested for both acute exposure (3 days) and chronic exposure (2 weeks). The combination screen showed that chronic treatment with 10 μM ambroxol showed the highest GCase activity in GBA cells (mean ± SD, ABX = 133659 ± 10542 compared to DMSO = 90302 ± 3986, 48% increase in GCase activity). This was further tested in LRRK2, SNCA, and GBA compared to AHN (Figure 12C). Twenty-one days after thawing, 2 weeks of treatment with 10 μM ambroxol significantly increased Gcase activity in all mutant neurons (on average, AHN from 165,052 to 171,669, GBA from 108,417 to 121,225 (12% increase), LRRK2 from 152,793 to 180,112 (18% increase), and SNCA from 165,107 to 189,082 (14% increase)) (dotted lines indicate Gcase levels in DMSO vehicle controls; *** P value < 0.001).

[0224] [Table 2]

[0225] For calcium imaging experiments, DA neurons were cultured as spheroids (50,000 / well) in 384 U-bottom ULA plates (S-bio plates) and fed with Brainphys complete medium (Brainphys basal medium + neural supplement A + NSS). Seven days after plating, some wells were treated with 10 μM ambroxol. Fourteen days after plating (seven days after treatment), cells were loaded into 1X EarlyTOX cardiotoxicity kit and incubated at 37 °C for 2 h, after which Ca2+ oscillations were captured for 20 min using the FDSS / μCELL instrument. Waveform software was used for quantification of Ca oscillations, and data were analyzed using GraphPad Prism.

[0226] Calcium oscillation traces of DA neurons 14 days after plating were captured for 20 min using the FDSS / μCELL instrument. Baseline measurements of Ca oscillations in AHN and all three mutations after one week of treatment with 10 μM ambroxol are shown in Figure 13A. Compared to untreated AHN DA neurons, treatment with ambroxol caused hyperexcitability in AHN, LRRK2, and SNCA DA neurons but rescued the peak number and peak rate in GBA mutant DA neurons. Calcium transient characteristics, including (Figure 13B) peak number, (Figure 13C) peak rate per minute, and (Figure 13D) area under the curve / peak (mean), were quantified for all wells (replicates) of each cell line using Waveform software. Peak numbers differed between mutations (disease neurons) compared to AHN (mean ± SD, AHN = 21.55 ± 3, GBA = 13.43 ± 1, LRRK2 = 28.83 ± 3.65, and SNCA = 24.5 ± 5.3). Ambroxol treatment increased peak numbers in all neurons, including AHN (mean ± SD, AHN = 33.75 ± 7.14, GBA = 21.8 ± 1.8, LRRK2 = 35.3 ± 3.9, and SNCA = 33.8 ± 1.5). Peak rates, the number of peaks per minute, also differed between cell lines (mean ± SD, AHN = 1.12 ± 0.16, GBA = 0.72 ± 0.06, LRRK2 = 1.52 ± 0.16, and SNCA = 1.26 ± 0.3) and were increased by treatment with ambroxol (mean ± SD, AHN = 1.74 ± 0.32, GBA = 1.13 ± 0.1, LRRK2 = 1.89 ± 0.18, and SNCA = 1.61 ± 0.12).The area under the curve, which is a measure of the time the calcium channel is open and / or a direct measurement of cytoplasmic calcium, also differs in mutant neurons compared to AHN (mean ± SD, AHN = 34.6E04 ± 13.5E04, GBA = 57.3E04 ± 13.4E04, LRRK2 = 27.4E04 ± 10.3E04, and SNCA = 41.3E04 ± 17.6E04), and ambroxol treatment decreased cytoplasmic calcium in GBA and SNCA but not in LRRK2 mutant DA neurons (mean ± SD, AHN = 25.7E04 ± 13.0E04, GBA = 38E04 ± 78E03, LRRK2 = 26.1E04 ± 49.5E03, and SNCA = 37.4E04 ± 41.7E03). The peak rate, which is the number of peaks per minute in normal and healthy cells, was 0.96 < AHN < 1.3 14 days after plating, and a 30% change was considered an abnormal peak rate. The average area under the curve of healthy neurons was 21.1E04 < AHN < 48.2E04, and a change in the area under the curve of more than 40% was considered an abnormal peak. The peak rate and the area under the curve (peaks) can be used as a readout for compound screening in diseased neurons when AHN functions as a control and a compound that may rescue these two parameters can be considered a positive hit in compound screening.

[0227] All methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. Although the compositions and methods of the invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the art that various changes can be applied to the methods and steps or series of steps described herein without departing from the concept, spirit, and scope of the invention. More specifically, it will be apparent that certain chemically and physiologically related agents can be used in place of the agents described herein, whereupon the same or similar results would be obtained. All such similar alternative and modified forms apparent to those skilled in the art are considered to be within the spirit, scope, and concept of the invention as defined by the appended claims. References The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. Andrews et al., In: Teratocarcinomas and Embryonic Stem Cells, Robertson (Ed.), IRL Press, 207-246, 1987. Chen et al.,Nature Methods 8:424-429,2011. Evans et.al., Nature, 292:154, 1981. Fernandes, et al., J. Biotechnology, 132(2):227-236, 2007. Gaj et al.,Trends in Biotechnology,2013, 31(7),397-405 Gene Targeting, A Practical Approach, IRL Press at Oxford University Press, 1993. International Patent Publication No.2012 / 149484 A2 International Patent Publication No.98 / 30679 International Patent Publication No.PCT / US2011 / 046796 International Patent Publication No.WO 02 / 016536 International Patent Publication No.WO 03 / 016496 International Patent Publication No.WO 2009 / 149233 International Patent Publication No.WO 2010 / 141801 International Patent Publication No.WO 2011 / 091048 International Patent Publication No.WO 98 / 30679 International Patent Publication No.WO 98 / 53058 International Patent Publication No.WO 98 / 53059 International Patent Publication No.WO 98 / 53060 International Patent Publication No.WO01 / 088100 International Patent Publication No.WO2005 / 080554 International Patent Publication No.WO2005 / 123902 International Patent Publication No.WO2011130675 International Patent Publication No.WO2012080248 International Patent Publication No.WO2013 / 067362 International Patent Publication No.WO2013067362 International Patent Publication No.WO2013163228 Jainchill et al.,J.Virol.,4:549,1969. Kodama et al.,J.Cell.Physiol.,112:89,1982. Ludwig et al.,Nat.Biotechnol.,24(2):185-187, 2006b. Ludwig et al.,Nat.Methods 3(8):637-46, 2006a. Manipulating the Mouse Embryo A Laboratory Manual, Second Edition,Cold Spring Harbor Laboratory Press, 1994. Martin,Proc.Natl. Acad.Sci.USA,78:7634, 1981. Nakano et al. Science,272,722,1996. Takahashi and Yamanaka,Cell,126:663-676,2006. Takahashi et al.,Cell,131:861-872,2007. U.S.Application No.13 / 054,022 U.S.Patent No.8,252,586 U.S.Patent No.8,426,200 U.S.Patent No.6,140,081 U.S.Patent No.6,453,242 U.S.Patent No.6,534,261 U.S.Patent No.7,820,439 U.S.Patent No.8,153,428 U.S.Patent Publication No.2011 / 0053207 U.S.Patent Publication No.2014 / 0038279 U.S.Patent Publication No.2002 / 0076747 U.S.Patent Publication No.2003 / 0211603 U.S.Patent Publication No.2005 / 0064474 U.S.Patent Publication No.2006 / 0188987 U.S.Patent Publication No.2007 / 0116680 U.S.Patent Publication No.2007 / 0218528 U.S.Patent Publication No.2007 / 0238170 U.S.Patent Publication No.2008 / 0171385 U.S.Patent Publication No.2008 / 0171385 U.S.Patent Publication No.2011 / 0301073 U.S.Patent Publication No.2011 / 0301073 U.S.Patent Publication No.2012 / 0276063 U.S.Patent Publication No.2012 / 0276063 Watanabe et al.,Nature Neurosci.,8:288-296,2005. Yakubov et al., Biochemical and Biophysical Research Communications 394:189-193,2010. Yu and Thomson,Genes Dev. 22(15):1987-97,2008. Yu et al.,Science,318:1917-1920,2007. Yu et al.Science,324(5928):797-801,2009.

Claims

1. Dopaminergic (DA) neuronal cell lines derived from isolated induced pluripotent stem cells (iPSCs) containing a glucosylceramidase (GBA) mutation, a leucine-rich repeat kinase 2 (LRRK2) mutation, or an alpha-synuclein (SNCA) mutation.

2. The cell line of claim 1 , which has a GBA mutation.

3. The cell line of claim 2 , which has a GBA N370S mutation or a LRRK2 G2019S mutation.

4. The cell line of claim 2 , having a GBA N370S mutation, a GBA L444P mutation, or a GBA RecNil mutation.

5. The cell line of claim 2 , which has a GBA N370S mutation.

6. The cell line of claim 1 , which has an LRRK2 mutation.

7. The cell line of claim 1 , having an LRRK2 G2019S mutation, an LRRK2 R1441G mutation, an LRRK2 R1441C mutation, or an LRRK2 I2020T mutation.

8. The cell line of claim 1 , which has an LRRK2 G2019S mutation.

9. The cell line of claim 1 , which has an SNCA mutation.

10. The cell line of claim 1 , having an SNCA A53T mutation, an SNCA E46K mutation, an SNCA duplication, or an SNCA triplication.

11. The cell line of claim 1 , which has an SNCA A53T mutation.

12. The cell line of any one of claims 1 to 8, wherein the iPSCs of the iPSC-derived DA neuron cell line are episomally reprogrammed iPSCs from a donor with a neurodegenerative disease.

13. The cell line of any one of claims 1 to 8, wherein the iPSCs of the iPSC-derived dopaminergic neuron cell line are episomally reprogrammed iPSCs from a Parkinson's disease donor.

14. 12. The cell line of any one of claims 1 to 11, wherein the iPSC-derived dopaminergic neuron iPSCs are genetically engineered to contain a GBA mutation, a LRRK2 mutation, or a SNCA mutation.

15. The cell line according to any one of claims 1 to 15, which is a human cell line.

16. The cell line of any one of claims 1 to 15, wherein the iPSC-derived dopaminergic neurons are midbrain dopaminergic neurons.

17. The cell line of any one of claims 1 to 15, wherein the iPSC-derived dopaminergic neurons are terminal dopaminergic neurons that express FOXA2 and tyrosine hydroxylase (TH).

18. 18. The cell line of any one of claims 1-17, wherein the iPSC-derived dopaminergic neurons have at least 50% increased TH, DDC, MAOA, and / or COMT transcript levels compared to DA neurons differentiated from iPSCs reprogrammed from healthy donors not carrying disease-associated mutations.

19. 19. The cell line of any one of claims 1-18, wherein the iPSC-derived dopaminergic neurons have at least 30% increased release of dopamine in response to KCl stimulation compared to DA neurons differentiated from iPSCs reprogrammed from healthy donors not carrying a disease-associated mutation.

20. 20. The cell line of any one of claims 1-19, wherein the iPSC-derived dopaminergic neurons exhibit increased cell death, mitochondrial stress, and alpha-synuclein protein aggregation compared to DA neurons differentiated from iPSCs reprogrammed from healthy donors that do not harbor disease-associated mutations.

21. The cell line of any one of claims 1 to 20, which is isogenic.

22. 21. The cell line of any one of claims 1 to 20, wherein the iPSC-derived dopaminergic neurons containing an SNCA mutation have reduced lysosomal GCase activity compared to DA neurons differentiated from iPSCs reprogrammed from healthy donors that do not carry the disease-associated mutation.

23. 21. The cell line of any one of claims 1 to 20, wherein the iPSC-derived dopaminergic neurons containing an SNCA mutation have reduced lysosomal GCase activity compared to DA neurons differentiated from iPSCs reprogrammed from healthy donors that do not carry the disease-associated mutation.

24. 21. The cell line of any one of claims 1 to 20, wherein the iPSC-derived dopaminergic neurons lack intracellular calcium signaling as measured by RNA sequencing and calcium imaging.

25. A kit comprising the cell line according to any one of claims 1 to 21 in a suitable container.

26. 26. The kit of claim 25, comprising an iPSC-derived DA neuron cell line comprising a GBA mutation disposed in a first container, and an iPSC-derived DA neuron cell line comprising an LRRK2 mutation disposed in a second container.

27. 26. The kit of claim 25, comprising an iPSC-derived DA neuron cell line comprising a GBA N370S mutation disposed in a first container, and an iPSC-derived DA neuron cell line comprising a LRRK2 G2019S mutation disposed in a second container.

28. 26. The kit of claim 25, further comprising an iPSC-derived DA neuron cell line that does not harbor a disease-associated mutation.

29. 29. The kit of claim 28, wherein the iPSC-derived DA neuron cell line iPSCs are episomally reprogrammed iPSCs from a healthy donor.

30. 30. The kit of claim 29, wherein the healthy donor is free of a neurodegenerative disease.

31. The kit of any one of claims 25 to 30, further comprising an iPSC-derived DA neuron cell line engineered to express a disease-associated mutation, disposed in a third container.

32. The kit of claim 31 , wherein the disease-associated mutation is a mutation in alpha-synuclein (SNCA).

33. The kit of claim 32, wherein the SNCA mutation is a missense point mutation.

34. 34. The kit of claim 33, wherein the missense point mutation is A53T.

35. 28. The kit of claim 25 or 27, further comprising astrocytes, pericytes, brain microvascular endothelial cells, microglia, and / or neurons, each contained in a suitable container.

36. 36. The kit of any one of claims 25 to 35, further comprising reagents for detecting dopamine levels, GBA activity, Neuronal Maestro Multi-Electrode Array (MEA) multiactivity, and reduction of alpha-synuclein mediated protein aggregation, each contained in a suitable container.

37. The kit of any one of claims 25 to 36, further comprising reagents for measuring TH, DDC, MAOA, and / or COMT transcription levels.

38. The kit according to any one of claims 25 to 37, further comprising a reagent for detecting glucocerebrosidase (GCase) activity and / or a reagent for performing calcium imaging.

39. 37. The kit of claim 36, wherein the reagents are further defined as enzyme-linked immunosorbent assay (ELISA) reagents.

40. 40. The kit of claim 39, further comprising an ELISA plate.

41. Use of a kit according to any one of claims 25 to 40 for the detection of a neurodegenerative disease.

42. 42. The use according to claim 41, wherein the neurodegenerative disease is Parkinson's disease.

43. Use of a kit according to any one of claims 25 to 40 for screening therapeutic agents for the treatment of neurodegenerative diseases.

44. Use of the kit according to any one of claims 25 to 40 as a model for Parkinson's disease.

45. Cultures containing DA neurons derived from iPSCs containing GBA, LRRK2, or SNCA mutations.

46. The culture of claim 45, comprising DA neurons derived from iPSCs that contain a GBA N370S mutation, a LRRK2 G2019S mutation, or a SNCA A53T mutation.

47. The culture of claim 45, comprising DA neurons derived from iPSCs containing a GBA N370S mutation.

48. The culture of claim 45, comprising DA neurons derived from iPSCs that contain the LRRK2 G2019S mutation.

49. The culture of claim 45, comprising DA neurons derived from iPSCs containing an SNCA A53T mutation.

50. The culture of any one of claims 45 to 48, wherein the cell culture is a two-dimensional (2D) culture.

51. The culture of any one of claims 45 to 50, wherein the medium comprises DAPT.

52. The culture of any one of claims 45 to 51, wherein the cells are cultured on a surface coated with an extracellular matrix protein.

53. 53. The culture of claim 52, wherein the extracellular matrix protein is basement membrane extract (BME) purified from mouse Engelbreth-Holm-Swarm tumors.

54. 53. The culture of claim 52, wherein the extracellular matrix protein is MATRIGEL®, GELTREX™, collagen, or laminin.

55. 55. The culture of any of claims 45 to 54, wherein the cell culture is a three-dimensional (3D) culture.

56. 56. The culture of any one of claims 47 to 55, wherein the cell culture further comprises astrocytes, pericytes, brain microvascular endothelial cells, microglia, and / or neurons.

57. The culture of any one of claims 45 to 56, wherein the iPSCs are human.

58. 58. The culture of any one of claims 45 to 57, which is xeno-free, feeder-free, and / or conditioned medium-free.

59. The culture of any one of claims 45 to 58, wherein the medium is a defined medium.

60. 60. Use of a culture according to any one of claims 45 to 59 as a model for a neurodegenerative disease.

61. 61. The use of claim 60, wherein the model comprises a culture containing DA neurons derived from iPSCs containing a GBA N370S mutation, DA neurons derived from iPSCs containing a LRRK2 G2019S mutation, DA neurons derived from iPSCs from healthy donors, or DA neurons derived from iPSCs engineered to express an SNCA A53T mutation.

62. 60. A method of screening for therapeutic compounds for treating a neurodegenerative disease comprising contacting a test compound with an iPSC-derived DA neuron according to any one of claims 1 to 16 or a culture according to any one of claims 45 to 59, and measuring the functional activity, physiology, or viability of the cells.

63. 63. The method of claim 62, wherein an increase in functional activity indicates that the test compound is capable of treating a neurodegenerative disease.

64. 64. The method of claim 62 or 63, comprising measuring the level of dopamine.

65. 66. The method of any one of claims 62 to 65, further comprising contacting the cell line with KCl.

66. 66. The method of any one of claims 62 to 65, wherein measuring the functional activity comprises measuring GBA activity, MEA activity, alpha-synuclein mediated protein aggregation, and / or mitochondrial ROS levels.

67. 67. The method of any one of claims 62 to 66, wherein measuring the functional activity comprises measuring glucocerebrosidase (GCase) activity.

68. 68. The method of claim 67, wherein an increase in GCase activity of at least 10% identifies a candidate compound.

69. 68. The method of claim 67, further comprising performing a calcium imaging assay to measure calcium oscillations.

70. 70. The method of claim 69, wherein measuring calcium oscillations comprises measuring one or more of the measurements selected from the group consisting of peak number, peak rate, and area under the curve.

71. 71. The method of claim 70, wherein the measured calcium oscillations can be associated with AHN neurons or mutant neurons.

72. 71. The method of claim 70, wherein measuring calcium oscillations can be used for compound screening.

73. 65. The method of claim 64, wherein the level of dopamine is measured by an ELISA assay.

74. 74. The method of claim 73, wherein the ELISA assay is a competitive dopamine ELISA.

75. 75. The method of any one of claims 64 to 74, wherein measuring the level of dopamine comprises measuring dopamine mRNA and / or protein levels.

76. 75. The method of any one of claims 64-74, wherein an increase in dopamine of at least 30% or greater than 30 ng / mL is indicative of a candidate compound.

77. 77. The method of any one of claims 62 to 76, further comprising measuring TH, DDC, MAOA, and COMT transcript levels.

78. 67. The method of claim 66, wherein alpha-synuclein protein aggregation is measured by thioflavin staining and alpha-synuclein expression.

79. 79. The method of any one of claims 62 to 78, wherein the neurodegenerative disease is Parkinson's disease.

80. 80. The method of any one of claims 62-79, wherein at least a 1.5-fold increase in TH, DDC, MAOA, and / or COMT RNA expression identifies a candidate compound.

81. The method of any one of claims 62 to 79, wherein an increase in MEA activity identifies a candidate compound.

82. The method of any one of claims 62 to 79, wherein an increase of at least 30% in alpha-synuclein expression and aggregation and / or mitochondrial ROS identifies a candidate compound.

83. 80. The method of any one of claims 62 to 79, wherein a decrease in GBA activity of at least 50% identifies a candidate compound.

84. A method for screening for a neurodegenerative disease, comprising contacting an iPSC-derived DA neuron containing a GBA mutation or an LRRK2 mutation with a sample.

85. 85. The method of claim 84, wherein screening for a neurodegenerative disease comprises contacting an iPSC-derived DA neuron comprising a GBA N370S mutation or a LRRK2 G2019S mutation with the sample.

86. 86. The method of claim 84 or 85, further comprising contacting an iPSC-derived DA neuron containing an SNCA A53T mutation with the sample.

87. The method of claim 84 or 86, wherein the iPSC-derived DA neuron comprising the GBA N370S mutation and / or the iPSC-derived DA neuron comprising the LRRK2 G2019S mutation is a cell according to any one of claims 1 to 16.

88. The method of any one of claims 84 to 87, wherein the sample is a patient sample.

89. The method of any one of claims 84 to 88, wherein the sample is a blood sample.

90. 90. The method of any one of claims 87 to 89, further comprising detecting the level of dopamine.

91. 91. The method of claim 90, wherein an increased level of dopamine indicates the presence of a neurodegenerative disease.

92. 92. The method of any one of claims 84 to 91, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, or multiple sclerosis.

93. The method according to any one of claims 84 to 91, wherein the neurodegenerative disease is Parkinson's disease.